



National Toxicology Program
U.S. Department of Health and Human Services

REPORT ON CARCINOGENS

MONOGRAPH ON *HELICOBACTER PYLORI* (CHRONIC INFECTION)

RoC MONOGRAPH 14

OCTOBER 2018

Report on Carcinogens Monograph on *Helicobacter pylori* (Chronic Infection)

RoC Monograph 14

October 2018

National Toxicology Program
Public Health Service
U.S. Department of Health and Human Services
ISSN: 2331-267X

Research Triangle Park, North Carolina, USA

Foreword

The National Toxicology Program (NTP), established in 1978, is an interagency program within the Public Health Service of the U.S. Department of Health and Human Services. Its activities are executed through a partnership of the National Institute for Occupational Safety and Health (part of the Centers for Disease Control and Prevention), the Food and Drug Administration (primarily at the National Center for Toxicological Research), and the National Institute of Environmental Health Sciences (part of the National Institutes of Health), where the program is administratively located. NTP offers a unique venue for the testing, research, and analysis of agents of concern to identify toxic and biological effects, provide information that strengthens the science base, and inform decisions by health regulatory and research agencies to safeguard public health. NTP also works to develop and apply new and improved methods and approaches that advance toxicology and better assess health effects from environmental exposures.

The Report on Carcinogens Monograph series began in 2012. Report on Carcinogens Monographs present the cancer hazard evaluations of environmental agents, substances, mixtures, or exposure circumstances (collectively referred to as “substances”) under review for the [Report on Carcinogens](#). The Report on Carcinogens is a congressionally mandated, science-based, public health document that provides a cumulative list of substances that pose a cancer hazard for people in the United States. Substances are reviewed for the Report on Carcinogens to (1) be a new listing, (2) reclassify the current listing status, or (3) be removed.

NTP evaluates cancer hazards by following a multistep process and using established criteria to review and integrate the scientific evidence from published human, experimental animal, and mechanistic studies. General instructions for the systematic review and evidence integration methods used in these evaluations are provided in the [Handbook for the Preparation of Report on Carcinogens Monographs](#). The handbook’s instructions are applied to a specific evaluation via a written protocol. The evaluation’s approach as outlined in the protocol is guided by the nature, extent, and complexity of the published scientific information and tailored to address the key scientific issues and questions for determining whether the substance is a potential cancer hazard and should be listed in the Report on Carcinogens. Draft monographs undergo external peer review before they are finalized and published.

The Report on Carcinogens Monographs are available free of charge on the [NTP website](#) and cataloged in [PubMed](#), a free resource developed and maintained by the National Library of Medicine (part of the National Institutes of Health). Data for these evaluations are included in the [Health Assessment and Workspace Collaborative](#). Information about the Report on Carcinogens is also available on the NTP website.

For questions about the monographs, please email [NTP](#) or call 984-287-3211.

Table of Contents

Foreword.....	ii
Tables.....	iv
About This Report.....	v
Peer Review	vii
Publication Details	viii
Acknowledgments.....	viii
Abstract.....	ix
1. Objective and Methods	1
1.1. Objective	1
1.2. Monograph Development and Contents.....	1
1.3. Methods for Conducting the Cancer Hazard Evaluation	2
1.3.1. Selection of the Literature.....	2
1.3.2. Evaluation of Human Cancer Studies	2
1.3.3. Evaluation of Cancer Studies in Experimental Animals.....	3
1.3.4. Evaluation of Mechanistic and Other Relevant Data.....	3
1.3.5. Overall Evaluation and Listing Recommendation.....	3
1.4. Method for Developing the Section on Prevention of <i>H. pylori</i> -associated Cancer	4
2. <i>Helicobacter pylori</i> (Chronic Infection) Substance Profile.....	5
2.1. Biological Properties	5
2.2. Detection	6
2.3. Exposure.....	7
2.3.1. Transmission	8
2.3.2. Diseases (Noncancer), Treatment, and Prevention	9
2.4. Carcinogenicity	10
2.4.1. Cancer Studies in Humans	10
2.4.2. Cancer Studies in Experimental Animals	12
2.4.3. Mechanisms of Carcinogenesis and Other Relevant Data.....	12
2.4.4. NTP's Listing Recommendation.....	14
2.5. Regulations.....	14
2.5.1. Department of Transportation (DOT).....	14
2.5.2. Food and Drug Administration (FDA, an Agency of Health and Human Services).....	14
2.5.3. Occupational Safety and Health Administration (OSHA).....	14
3. Prevention of <i>H. pylori</i> -associated Cancer	15
3.1. Prevention of <i>H. pylori</i> -induced Cancers: State of the Science	15
3.1.1. Screening for and Treatment of <i>H. pylori</i> Infection	16
3.1.2. Efficacy and Effectiveness of <i>H. pylori</i> Eradication in Preventing Stomach Cancer	16
3.1.3. Cost-benefit Analyses Studies	22
3.1.4. Issues and Concerns.....	24

3.2. Policies and Recommendations.....	25
3.2.1. National Consensus Recommendations for the Prevention of <i>H. pylori</i> - induced Cancer	25
3.2.2. Screening and Treatment Programs.....	27
3.3. Summary of the Recommendations of International Expert Working Groups (Including the IARC Working Group).....	28
References.....	29
Abbreviations.....	43
Glossary	44
Appendix A. Literature Search Strategy.....	A-1
Appendix B. Summary of Human Studies of Pancreatic and Colorectal Cancer.....	B-1

Tables

Table 2-1. Methods for Detection of <i>H. pylori</i> Infection.....	6
Table 3-1. Randomized Controlled Trials of <i>H. pylori</i> Eradication and the Incidence of Gastric Cancer	17
Table 3-2. Meta-analyses of Randomized Controlled Trials and Cohort Studies Investigating the Effectiveness of <i>H. pylori</i> Eradication in Reducing Gastric Cancer Incidence	21
Table 3-3. Recommendations for Prevention of <i>H. pylori</i> -induced Cancer	26

This report has been reformatted to meet new NTP publishing requirements;
its content has not changed.

About This Report

National Toxicology Program¹

¹Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

Collaborators

Ruth M. Lunn, Whitney Arroyave

Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

Executed and coordinated project activities, including conception, design, planning, conduct, or technical review of cancer hazard evaluation

Ruth M. Lunn, Dr.P.H., Project Co-lead

ILS, Inc., Research Triangle Park, North Carolina, USA

Executed and coordinated project activities, including conception, design, planning, conduct, or technical review of cancer hazard evaluation

Whitney Arroyave, Ph.D., Project Co-lead

Contributors

RoC Internal Review Group

Provided critical scientific review of the draft monograph prior to external peer review and public release

John Bucher, Ph.D., Chair, DNTP, NIEHS

Brandy Beverly, Ph.D., DNTP, NIEHS

Michelle Hooth, Ph.D., DNTP, NIEHS

David Malarkey, Ph.D., DNTP, NIEHS

Scott M. Masten, Ph.D., DNTP, NIEHS

Suril Mehta, M.P.H., DNTP, NIEHS

Charles Rabkin, M.D., Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA

Amy Wang, Ph.D., DNTP, NIEHS

Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

Provided technical assistance with the monograph preparation

Gloria Jahnke, D.V.M., DABT

Organized the peer review meeting

Elizabeth A. Maull, Ph.D.

Mary S. Wolfe, Ph.D.

ILS, Inc., Research Triangle Park, North Carolina, USA

Provided technical assistance with the monograph preparation

Andrew Ewens, Ph.D.

Sanford Garner, Ph.D.

Lara Handler, M.S.L.S.

Alton Peters, M.S.

Provided administrative assistance

Ella J. Darden, B.S.

Tracy L. Saunders, B.S.

Conducted literature searches

Jessica A. Geter, M.S.L.S.

ICF International, Inc., Durham, North Carolina, USA

Provided editorial assistance

Susan Dakin, Ph.D.

Provided logistical support for the peer review meeting

Canden Byrd, B.S.

Kelly Shipkowski, Ph.D.

Peer Review

The Draft Report on Carcinogens Monograph on *Helicobacter pylori* (chronic infection) was peer reviewed by letter by individuals with expertise in *H. pylori* and cancer. The reviewers served as independent scientists and not as representatives of any institution, company, or governmental agency.

The peer reviewers were charged to:

- 1) Comment on whether the draft monograph was technically correct, clearly stated, and objectively presented.
- 2) Provide opinion on whether there is currently or was in the past significant human exposure to *H. pylori*.

Each peer reviewer independently was asked to provide opinion on:

- 1) Whether the scientific evidence supported the NTP's preliminary conclusion on the level of evidence for carcinogenicity from cancer studies in humans.
- 2) Whether the scientific evidence supported the NTP's preliminary policy decision on *H. pylori* for listing in the Report on Carcinogens.

The monograph was revised based on NTP's consideration of the peer-review comments.

Peer Reviewers

Rolando Herrero, M.D., Ph.D.

Head

Prevention and Implementation Group

Early Detection and Prevention Section

International Agency for Research on Cancer

Lyon, France

Julie Parsonnet, M.D.

George DeForest Barnett Professor in Medicine

Professor of Medicine

Professor of Health Research and Policy

Division of Infectious Diseases and Geographic Medicine

Division of Epidemiology

Stanford University Medical Center

Stanford, California, USA

Traci L. Testerman, Ph.D.

Assistant Professor

Department of Pathology, Microbiology, and Immunology

University of South Carolina School of Medicine

Columbia, South Carolina, USA

Publication Details

Publisher: National Toxicology Program

Publishing Location: Research Triangle Park, NC

ISSN: 2331-267X

DOI: <https://doi.org/10.22427/ROC-MGRAPH-14>

Report Series: RoC Monograph Series

Report Series Number: 14

Official citation: National Toxicology Program (NTP). 2018. Report on Carcinogens monograph on *Helicobacter pylori* (chronic infection). Research Triangle Park, NC: National Toxicology Program. RoC Monograph 14.

Acknowledgments

This work was supported by the Intramural Research Program (ES103316 and ES103317) at the National Institute of Environmental Health Sciences, National Institutes of Health and performed for the National Toxicology Program, Public Health Service, U.S. Department of Health and Human Services under contract GS00Q14OADU417 (Order No. HHSN273201600015U).

Abstract

Helicobacter pylori is a gram-negative, multi-flagellated bacterium that colonizes the stomach and causes peptic ulcers. More than half the world's population is infected with *H. pylori* with the highest prevalence rates in low- and middle-income countries. The bacterium is spread via person-to-person contact, especially among people of lower socioeconomic status living in crowded conditions and often with poor sanitation. Several international health working groups have linked *H. pylori* with an increased risk of gastric cancer. Because of these public health concerns, the National Toxicology Program (NTP) conducted a literature-based cancer hazard assessment of *H. pylori* and recommended that *H. pylori* be listed as a *known human carcinogen* in the Report on Carcinogens (RoC), a U.S. Congress-mandated document that provides information on cancer hazards for people residing in the United States. The RoC monograph on *H. pylori* provides a concise review of the evidence from cancer studies in humans and experimental animals, as well as information on human exposure to *H. pylori*. As *H. pylori* is thought to account for 6.2% of all cancer deaths in the world, primarily due to non-cardia gastric cancer, the monograph also provides a summary of the state of the science for prevention of *H. pylori*-induced cancer, including a review of the effectiveness of intervention studies, cost-benefit analyses, international working group recommendations, and issues and concerns related to programs that would screen people for *H. pylori* infection and treat those who are infected with antibiotics.

1. Objective and Methods

1.1. Objective

Helicobacter pylori is a gram-negative, multi-flagellated bacterium that colonizes the luminal mucosal surface of the body (corpus) and lower portion (antrum) of the stomach; if untreated, the infection usually lasts for the individual's lifetime. Chronic infection can cause gastritis and peptic ulcers.

The objective of this monograph is to present NTP's conclusions regarding the level of evidence for carcinogenicity from studies in humans and experimental animals and its Report on Carcinogens (RoC) listing recommendation. These conclusions were reached by applying the RoC listing criteria to the cancer assessment.

The rationale for selecting *H. pylori* for review for the RoC and the approach to preparing the monograph were outlined in the draft concept document, "*Helicobacter pylori*: Chronic Infection" (NTP 2016). The draft concept document was released for public comment and presented to the NTP Board of Scientific Counselors at its meeting on April 11, 2016, which provided opportunity for written and oral public comments. After the meeting, the concept document was finalized, and *H. pylori* was approved by the NTP Director as a candidate substance for review. The concept document is available on the RoC website (NTP 2016).

1.2. Monograph Development and Contents

In developing the monograph, NTP relied on the International Agency for Research on Cancer assessment (IARC 2012) and peer review of the cancer studies in humans and experimental animals and mechanistic and other relevant data. The rationale for relying primarily upon the IARC monograph is that the role of *H. pylori* as the major risk factor for stomach cancer is well established in the scientific community [see the concept document, NTP (2016)].

H. pylori infection is responsible for approximately 780,000 cancer cases annually worldwide (Plummer et al. 2015). The current question for the health community is not about causation, but whether *H. pylori* screening and eradication programs should be implemented and, if so, how these prevention strategies should be carried out. Therefore, this monograph also reports on the status of activities for preventing *H. pylori*-induced stomach cancer. Providing information on activities to reduce exposure is consistent with the spirit of the congressional mandate for the RoC (as the report is expected to discuss Federal agency regulations to limit exposure) and should facilitate hazard communication efforts when the RoC monograph is published.

The monograph consists of the following sections:

- Objective and methods (Section 1), including methods for conducting the cancer hazard evaluation (Section 1.3)
- Substance profile: Science supporting the listing recommendation (Section 2)
- Status and summary of cancer prevention strategies (Section 3)
- Appendices: Literature search strategies and a summary of human studies of *H. pylori* infection and pancreatic and colorectal cancer

The substance profile includes a description of the substance, discussion of exposure-related data, a summary of the scientific information considered key to its listing, and applicable current federal regulations and guidelines to limit exposure. If *H. pylori* is listed in the 15th RoC, then the substance profile (but not the other sections of the monograph) will become part of the RoC. The profile is written for a broad audience.

1.3. Methods for Conducting the Cancer Hazard Evaluation

As outlined in the concept document, NTP conducted several problem-formulating activities. These included searching the peer-reviewed literature (1) to determine the extent of U.S. exposure to *H. pylori* and (2) to identify any potential controversies concerning IARC's assessment or any reports of cancer studies published since the IARC review whose findings were not consistent with findings from the earlier studies. Based on these literature searches, no information was identified that would argue against using the IARC assessment as the scientific basis for applying the RoC listing criteria and reaching a listing recommendation. NTP did not conduct its own systematic review of the primary cancer studies in humans and experimental animals.

The scientific information in the substance profile and cancer prevention strategies sections underwent scientific review and quality assurance review by a separate reviewer. The information in the profile was checked against the cited reference (e.g., IARC monograph, primary reference, review, or meta-analysis). Any discrepancies were resolved between the writer and the reviewer through discussion and reference to the original data source.

1.3.1. Selection of the Literature

NTP supplemented the IARC assessment and peer review of the cancer studies in humans and experimental animals and mechanistic studies (IARC 2012) with recent reviews or meta-analyses on cancer and mechanistic studies and exposure information. NTP also reviewed individual studies (cited in reviews, the IARC monograph, or other publications) when information in the IARC monograph was not clear or was related to a specific scientific issue.

Details on the literature search procedures and search terms are available in Appendix A.

1.3.2. Evaluation of Human Cancer Studies

NTP applied the RoC listing criteria (shown at the end of Section 1.3) to the body of literature to reach a decision on the level of evidence (sufficient, limited, or inadequate) for carcinogenicity based on cancer studies in humans. Human cancer studies on *H. pylori* infection were reported in the most recent IARC monograph on *H. pylori* (IARC 2012). NTP supplemented this information with a few more-recent studies that addressed key issues, such as information regarding chronic infection.

NTP focused on the two cancer outcomes for which IARC concluded there was sufficient evidence of carcinogenicity from studies in humans: stomach cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma (IARC 2012), [Tables 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, and 2.7](#)). Evidence was considered to be lacking for *H. pylori* as a cause of esophageal cancer (adenocarcinoma). In evaluating the human cancer data, NTP considered (1) IARC working-group comments on the strengths and limitations of the studies, (2) the consistency of a positive

association across studies, (3) patterns such as exposure-response or latency relationships, (4) effect modifiers or co-factors, and (5) whether the association across studies could be explained by chance, bias, or confounding. The science supporting the NTP level-of-evidence conclusions is captured in the substance profile (Section 2).

With respect to other types of cancer, the IARC working group expressed concerns about the quality of the studies or the small numbers of studies available (IARC 2012). NTP also reviewed recent meta-analyses, systematic reviews, and other reviews evaluating the association of *H. pylori* infection with other types of cancer, primarily pancreatic and colorectal cancer. In general, primary studies on these two types of cancer were identified from the meta-analyses or cited references. Based on the review of recent studies and of the IARC monograph, NTP concluded that no formal cancer hazard evaluation of pancreatic or colorectal cancer was warranted. A short summary of the updated findings on pancreatic and colorectal cancer is provided in Appendix B.

1.3.3. Evaluation of Cancer Studies in Experimental Animals

NTP applied the RoC listing criteria to the body of literature to reach a decision on the level of evidence (sufficient or not sufficient) from cancer studies in experimental animals. NTP accepted IARC's conclusions concerning the association between *H. pylori* infection and specific types of tumors (e.g., gastric adenocarcinoma and gastric lymphoma) in various animal models to determine whether the increases in tumors occurred at multiple tissue sites or in multiple species, or whether tumors occurred to an unusual degree with respect to incidence, site, type of tumor, or age at onset. In evaluating the data on cancer in experimental animals, NTP considered sources of heterogeneity across studies, such as differences in *H. pylori* strain, animal strain, or experimental methods, such as study duration.

1.3.4. Evaluation of Mechanistic and Other Relevant Data

The objective of the section on mechanistic and other relevant data is to provide a concise overview of the pathogenesis of *H. pylori* chronic infection and potential mechanisms of *H. pylori* carcinogenicity. As mentioned above, the substance profile is written for a broad audience, and its purpose is to provide an overview of the information that was key to the listing recommendation. Therefore, this section does not provide a detailed, comprehensive assessment of the mechanistic data or develop proposed modes of action. However, the section does evaluate whether the available mechanistic data provide biological plausibility for the findings observed in humans.

1.3.5. Overall Evaluation and Listing Recommendation

The evidence from the cancer studies in humans and experimental animals was integrated with the assessment of the mechanistic and other relevant data. The RoC listing criteria were then applied to the body of knowledge to reach a listing recommendation regarding chronic infection with *H. pylori*.

RoC Listing Criteria

Known to Be Human Carcinogen

There is sufficient evidence of carcinogenicity from studies in humans*, which indicates a causal relationship between exposure to the agent, substance, or mixture, and human cancer.

Reasonably Anticipated to Be Human Carcinogen

There is limited evidence of carcinogenicity from studies in humans*, which indicates that causal interpretation is credible, but that alternative explanations, such as chance, bias, or confounding factors, could not adequately be excluded, OR

there is sufficient evidence of carcinogenicity from studies in experimental animals, which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors (1) in multiple species or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site, or type of tumor, or age at onset, OR

there is less than sufficient evidence of carcinogenicity in humans or laboratory animals; however, the agent, substance, or mixture belongs to a well-defined, structurally related class of substances whose members are listed in a previous Report on Carcinogens as either known to be a human carcinogen or reasonably anticipated to be a human carcinogen, or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.

Conclusions regarding carcinogenicity in humans or experimental animals are based on scientific judgment, with consideration given to all relevant information. Relevant information includes, but is not limited to, dose response, route of exposure, chemical structure, metabolism, pharmacokinetics, sensitive sub-populations, genetic effects, or other data relating to mechanism of action or factors that may be unique to a given substance. For example, there may be substances for which there is evidence of carcinogenicity in laboratory animals, but there are compelling data indicating that the agent acts through mechanisms which do not operate in humans and would therefore not reasonably be anticipated to cause cancer in humans.

*This evidence can include traditional cancer epidemiology studies, data from clinical studies, and/or data derived from the study of tissues or cells from humans exposed to the substance in question that can be useful for evaluating whether a relevant cancer mechanism is operating in people.

1.4. Method for Developing the Section on Prevention of *H. pylori*-associated Cancer

The purpose of the section is to provide information and summarize studies and expert working group recommendations related to the prevention of *H. pylori*-associated gastric cancers. The IARC working group report, “*Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer,” served as the basis for Section 3 of the monograph (IARC 2014). The information was supplemented with new studies that evaluated the effectiveness of screening and eradication, cost-benefit analysis, and expert or government recommendations or guidelines. NTP did not make an assessment of the studies or provide its own recommendations or policies. The scientific information in the cancer prevention strategies sections underwent scientific review and quality assurance review by a separate reviewer, in a process similar to that described for the substance profile.

2. *Helicobacter pylori* (Chronic Infection) Substance Profile

The substance profile provides a summary of the carcinogenicity information supporting NTP's listing recommendation for *Helicobacter pylori*, together with information on biological properties, detection methods, human exposure, and regulations to limit exposure. The exposure information includes data on transmission and risk factors, non-cancer diseases, treatment, and prevention.

2.1. Biological Properties

H. pylori is a gram-negative, spiral- (or helical-) shaped, multi-flagellated bacterium that has infected humans for more than 58,000 years. It is a member of the family Helicobacteraceae, which includes over 24 *Helicobacter* species that colonize gastric or enterohepatic tissues (i.e., intestinal tract, biliary tree, and liver). Some gastric *Helicobacter* species from animals that can also infect humans include *H. bizzozeroni*, *H. salomonis*, *H. felis*, *H. canadensis*, and *H. suis* (IARC 2012). Some *Helicobacter* species that cause non-gastric diseases (primarily liver diseases) in humans include *H. hepaticus*, *H. pullorum*, and *H. bilis* (Mateos-Muñoz et al. 2013).

H. pylori colonizes the mucosal surface of the body (corpus) and the lower portion (antrum) of the stomach. Colonization involves an interaction between the proteins of the bacterium's outer membrane and the epithelial cells of the stomach lining. One of the major *H. pylori* proteins involved in colonization is blood group antigen binding adhesin (BabA), which binds to blood group antigen A (IARC 2012). Although *H. pylori* triggers an immune response, the infected individual usually is unable to clear the infection; without treatment, an established infection usually lasts for the individual's lifetime (Logan and Walker 2001; Testerman and Morris 2014).

All *H. pylori* strains produce the enzyme urease, which converts urea to ammonia and carbon dioxide, raising the pH (decreasing the acidity) of the surrounding area. A neutral pH environment thus is created in the mucosal layer adjacent to the surface epithelium of the stomach, allowing the bacterium to grow (Testerman and Morris 2014). Other properties of the bacterium also facilitate a persistent infection. Its helical shape and flagella help it to propel itself through the viscous mucosa, and a chemotaxis system (by which an organism moves in response to a chemical stimulus) helps the bacterium avoid the acidic stomach environment and stay closer to the surface epithelium. A non-toxic lipopolysaccharide component of the bacterium's outer membrane may help reduce the infected individual's inflammatory response to the infection. After antibiotic treatment, *H. pylori* can sometimes be detected in the upper part of the stomach (Sachs et al. 2011).

The *H. pylori* genome codes for several virulence factors, including cytotoxin-associated gene A product (CagA) and vacuolating cytotoxin A (VacA), which vary geographically and across strains (IARC 2012; Yamaoka and Graham 2014). Moreover, there are variants of *H. pylori* CagA producing strains, such as strains that differ in types or numbers of motifs, that are involved in binding to host targets and increased activities (i.e., EPIYA motifs). These variant strains have different geographical distributions (Cover 2016). Humans can be infected with several *H. pylori* strains, which may then exchange DNA, promoting the spread of virulence factors and antibiotic resistance (IARC 2012).

2.2. Detection

Numerous methods for diagnosing and screening for *H. pylori* infection are available, including assays to detect the bacterium itself, its DNA, antigens, antibodies, and urease activity (Table 2-1). The types of samples used in these tests range in invasiveness from biopsy samples taken during endoscopy, to blood samples, to collection of saliva, stool, urine, and expired air (Diaconu et al. 2017; Kato et al. 2001; Testerman and Morris 2014). These methods are summarized in the table below. Biopsy samples can also be evaluated for gastric pathology. All of these tests have moderate to high sensitivity (80% to 100%) and specificity (75% to 100%); however, sensitivity and specificity may vary depending on the condition of the patient, and some methods require several samples. Sensitivity and specificity may also vary by population under study (Biranjia-Hurdoyal and Seetulsingh-Goorah 2016). The method of detection used depends in part on the purpose of the testing (e.g., selection of treatment method or population studies), cost and technical skills, and patient considerations, such as age.

Table 2-1. Methods for Detection of *H. pylori* Infection

Test	Agent	Type of Sample	Comment
Histology: staining (e.g., Diff-Quik, Giemsa, hematoxylin and eosin)	<i>H. pylori</i> organism	Stomach tissue biopsy	Sensitivity: 93%–96% Specificity: 98%–99% Several samples needed; high cost; should be performed only on selected samples, such as from patients with gastritis or using certain types of antibiotics
Culture	<i>H. pylori</i> organism	Stomach tissue biopsy	Sensitivity: 80%–98% Specificity: ~100% Used for antimicrobial sensitivity testing; high cost
Rapid urease testing	<i>H. pylori</i> activity (active organisms)	Stomach tissue biopsy	Sensitivity: 88%–95% Specificity: 95%–100%
Molecular methods (e.g., polymerase chain reaction)	<i>H. pylori</i> DNA or RNA	Stomach tissue biopsy; stool, saliva, or oral-cavity specimens	Sensitivity and specificity >95%
Serology testing using <i>H. pylori</i> antigens: enzyme-linked immunosorbent assay (ELISA), immunoblot	<i>H. pylori</i> antibodies (mainly immunoglobulin G [IgG])	Serum or plasma	Sensitivity: 85%–96% Specificity: 75%–95% False-negative results can occur with underlying atrophic gastritis or gastric cancer or lifelong infections
Urea breath test	<i>H. pylori</i> urease activity (active infection) by measuring carbon dioxide (CO ₂)	Expired air	Sensitivity: 90%–99% Specificity: 88%–98%
Stool antigen test (e.g., ELISA, immunocards)	<i>H. pylori</i> antigens (active infection)	Stool	Sensitivity: 94% Specificity: 92% Recommended for children

Sources: Diaconu et al. (2017); Reynders et al. (2012); Testerman and Morris (2014).

Serological tests (such as ELISA or immunoblot) to detect *H. pylori* antibodies are widely available and relatively inexpensive. They are used in epidemiological and prevalence studies and are recommended for screening and treatment programs to prevent chronic disease (Areia et al. 2013). Serology tests are not recommended for low prevalence areas due to low specificity (Chey et al. 2017). Antibodies to *H. pylori* can persist for life, so these tests thus detect both past and current infections. An advantage of serological tests is that they are not affected by recent antibiotic use or acid-suppression therapy (Testerman and Morris 2014); however, they are not useful for measuring antibiotic treatment efficacy (Diaconu et al. 2017), as antibody titers are slow to fall. The sensitivity and specificity of serological tests depends on the antigens used in the assay, the type of assay (e.g., ELISA vs. immunoblot), the immunoglobulin class tested (mainly IgG, but also IgA), and factors that vary among infected individuals (González et al. 2012; Reynders et al. 2012). False-negative results can occur in individuals with advanced stomach diseases (e.g., atrophic gastritis) or cancer, because the bacteria are cleared from the mucosa of the stomach as the disease progresses. Case-control studies using ELISA may therefore underestimate the risk associated with *H. pylori* infection, because they will underestimate the prevalence in case but not control subjects (González et al. 2012; IARC 2012). Studies using immunoblot with multiple antigens have high sensitivity (95% to 96%) and specificity (93% to 96%) for detecting *H. pylori* infection (Mitchell et al. 2008; Simán et al. 2007).

2.3. Exposure

More than half of the world's population, approximately 4.4 billion in 2015, are infected with *H. pylori* (Hooi et al. 2017). However, infection rates vary substantially within and among countries. In general, infection rates are related to socioeconomic status and levels of hygiene and are highest in low-income countries. Age-adjusted prevalence rates are particularly high (70% to 87%) in some countries in Africa, Latin America, the Caribbean, and Asia.

In the United States, approximately 30% to 36% of people are infected with *H. pylori*, the highest (ranging from 42% to up to 77%) prevalence being found among minority groups (e.g., the Alaskan indigenous population, Hispanics, and African Americans) and individuals born outside the United States, especially recent Asian immigrants (Hooi et al. 2017; Khalifa et al. 2010; Krueger et al. 2015; Siao and Somsouk 2014). The lowest prevalence is among non-Hispanic Whites with approximately 17% of people infected according to NHANES data (Krueger et al. 2015), although some more recent smaller studies report that this may be as low as 9% among Texans (Long Parma et al. 2017). Moreover, the prevalence of more virulent strains may be higher among minorities; for example, in a study of mostly low-income individuals in the southeastern United States, the risk of CagA-positive infection was higher among African-Americans than whites (Epplein et al. 2011).

The prevalence of *H. pylori* infection increases with increasing age (Krueger et al. 2015); however, the age of peak prevalence varies geographically with peak prevalence occurring at a younger age in lower income countries (50 years old) compared to higher income countries (over age 60). Geographical differences in *H. pylori* prevalence may be related, in part, to differences in the rate of acquisition early in life (Khalifa et al. 2010; Malnick et al. 2014). In low-income countries, initial infection often occurs in early childhood and chronic infection continues through adulthood. In contrast, in high-income countries, infection rates are low among young children and adolescents. The lower rate of infection among children may be due to the fact that

prevalence rates in most of the world (e.g., especially the United States, Korea, and Japan) have decreased with each successive generation (referred to as the “birth cohort effect”) but have remained stable in many lower-income countries (such as in Latin and South America). The decline in *H. pylori* prevalence is related to access to clean water, improvements in sanitation, and improved household hygiene (Balakrishnan et al. 2017). Although there have been decreases in *H. pylori* infection in many countries, the prevalence remains high in adults.

Areas of high prevalence of *H. pylori* are not always directly correlated with high risk areas of gastric cancer, e.g., *H. pylori* prevalence but not gastric cancer incidence is high in Africa (Hooi et al. 2017). In a study in Colombia, two populations with different risks of stomach cancer (high and low) had similar prevalence patterns of *H. pylori* infection at an early age, suggesting that age of acquisition of infection may not play a major role in explaining gastric cancer risk (Camargo et al. 2004). Geographical differences in gastric cancer incidence may be explained in part by *H. pylori* genotypes, co-exposures (such as diet), and patients characteristics (for more information, see Carcinogenicity).

2.3.1. Transmission

Data from the U.S. National Health and Nutrition Examination Survey (NHANES) suggest that risk factors for *H. pylori* infection include age, race or ethnicity (minority), socioeconomic status (low family income and lower education level), and crowded housing (Krueger et al. 2015). Studies in other countries have also identified age, socioeconomic status, crowding, and poor sanitation as major risk factors and have suggested that gender and genetic predisposition also may influence *H. pylori* prevalence rates (Khalifa et al. 2010).

The bacterium is spread by person-to-person contact, especially among family members. This occurs primarily via oral-to-oral transmission and possibly via gastro-oral transmission mediated by refluxed gastric juice or fecal-oral transmission. *H. pylori* has been isolated from the oral cavity, gastric juices, and fecal samples (Khalifa et al. 2010). A meta-analysis of 22 studies found that *H. pylori* infection in the oral cavity was significantly more common among subjects with gastric *H. pylori* infection than among subjects without gastric *H. pylori* infection (Zou and Li 2011).

H. pylori can also be transmitted indirectly by drinking of contaminated water or possibly in food or from animal reservoirs (Aziz et al. 2015; Bui et al. 2016; IARC 2012; Khalifa et al. 2010). The bacterium has been detected in surface, ground, and well water in the United States and in treated municipal, tap, well, and bottled water in other countries (such as Peru and Sweden), and *H. pylori* can remain viable in chlorinated water [reviewed by Aziz et al. (2015); IARC (2012)]. The U.S. Environmental Protection Agency considers *H. pylori* a drinking-water contaminant and a candidate for possible regulatory action under the Safe Drinking Water Act (Krueger et al. 2015; USEPA 2016). Some epidemiological studies, including a study using NHANES data (for people aged 3 to 19) found that using well water or other unpurified water is a risk factor for *H. pylori* infection (Aziz et al. 2015; Khalifa et al. 2010; Krueger et al. 2015). In Japan, *H. pylori* prevalence was substantially lower in a cohort of individuals born between the 1960s and 1980s (14%) than in cohorts born between 1927 (54%) and 1949 (42%), which could be the result of improvements in sanitary conditions, such as the introduction of municipal water supply in the 1950s to 1970s (Leja et al. 2016). NHANES data also indicated that soil-related occupations among adults are a risk factor for *H. pylori* infection, which suggests an environmental route of

transmission (Krueger et al. 2015). However, other factors (country of birth, childhood poverty/crowding, race-ethnicity) are most likely more important for transmission of *H. pylori* in the United States.

2.3.2. Diseases (Noncancer), Treatment, and Prevention

In 2005, the Nobel Prize in Physiology or Medicine was awarded to Barry Marshall and Robin Warren for their discovery that an infectious agent, *H. pylori*, causes gastritis and peptic ulcers (up to 80% of gastric ulcers and over 90% of duodenal ulcers) (Nobel Prize 2005). *H. pylori* infection is also associated with some non-stomach diseases, such as iron-deficiency anemia and immune thrombocytopenia purpura (a tendency to bleed easily because of reduced numbers of blood platelets), and may be associated with non-ulcer dyspepsia (indigestion), although this association is not clear (AlMalki 2008; Dore et al. 2016; Testerman and Morris 2014).

Many different therapies are used in the United States, but the American College of Gastroenterology's Clinical Guideline for Treatment of *H. pylori* Infection update in 2017 (Chey et al. 2017) indicates that first-line regimens approved by the U.S. Food and Drug Administration (FDA) are either (1) clarithromycin triple therapy, with that antibiotic in combination with a proton-pump inhibitor (PPI) and a second antibiotic for 14 days, or (2) bismuth quadruple therapy, with a bismuth salt, a PPI, and two antibiotics for 10 to 14 days. Due to high levels of antibiotic resistance, clarithromycin triple therapy should only be considered a first line treatment in areas where resistance among *H. pylori* patients is known to be low. Eradication of *H. pylori* infection in an individual can be affected by (1) patient-related factors (e.g., adherence to the treatment regimen, smoking, diabetes, genetic factors influencing metabolism of PPIs, and past antibiotic use) and (2) *H. pylori*-related factors. The susceptibility of *H. pylori* to specific antibiotics is the most important determinant of successful *H. pylori* treatment, and patterns of resistance to specific antibiotics can vary geographically (Chey et al. 2017; Malfertheiner et al. 2017). If first-line treatment fails, second-line or salvage therapy generally is based on local antibiotic resistance rates (where known) and an individual's previous antibiotic use. Globally, *H. pylori* eradication rates have declined as antibiotic resistance rates have increased (Thung et al. 2016). Currently, no *H. pylori* vaccine is available (CDC 2016; FDA 2017). Vaccine development efforts are ongoing, but no large scale vaccine efforts are taking place (Sutton and Boag 2018; Zeng et al. 2015).

Randomized controlled trials (clinical studies with control groups that receive placebos) have shown that screening and treatment of *H. pylori* reduces stomach-cancer risk by approximately 35% (Herrero et al. 2014; Park et al. 2013). Moreover, economic modeling studies, in both low- and high-prevalence countries, have shown that *H. pylori* eradication is cost-effective. However, effectiveness in reducing cancer risk depends on several factors, such as patient characteristics, screening methods, efficacy of *H. pylori* eradication, and the stage of *H. pylori*-associated gastric disease. *H. pylori* eradication may increase bacterial resistance to antibiotics, alter the normal gastrointestinal flora found in the body, and possibly increase the incidence of diseases for which *H. pylori* infection may offer protection, such as esophageal cancer and gastro-esophageal reflux disease (GERD). Numerous international and national working groups have recommended that planned programs should consider objective assessments of feasibility, effectiveness, program acceptance, cost-effectiveness, and adverse consequences relevant to the local area before implementation. (See Section 3 for more information on prevention strategies.)

2.4. Carcinogenicity

This section reviews the evidence for carcinogenicity in humans (Section 2.4.1) and experimental animals (Section 2.4.2) and mechanistic data (Section 2.4.3) that are key to NTP's listing recommendation (Section 2.4.4).

2.4.1. Cancer Studies in Humans

Worldwide, stomach cancer is the fifth most common type of cancer and third leading cause of death from cancer, with most cases occurring in low- and middle-income countries.

Adenocarcinoma accounts for over 90% to 95% of all stomach cancer (Balakrishnan et al. 2017), which can be broadly classified by the location in the stomach where the cancer develops:

(1) cardia gastric cancer develops in the first portion of the stomach, closest to the esophagus, and (2) non-cardia gastric cancer develops in more distal parts of the stomach, closer to the small intestine. Gastric lymphoma, which consists primarily of gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma, accounts for approximately 2% to 8% of all stomach tumors (Park and Koo 2014; Zullo et al. 2010b). Gastric MALT lymphoma is a type of extranodal B-cell lymphoma (i.e., not arising in lymph nodes or other lymphoid tissue) that is low-grade, slow growing, and very rare (with a worldwide incidence of 1 to 1.5 cases per 100,000 people) (Pereira and Medeiros 2014).

Stomach Cancer

Evidence that *H. pylori* causes stomach (non-cardia gastric) cancer in humans is based on (1) consistent evidence from numerous epidemiological studies on stomach cancer, (2) a pooled analysis of 12 epidemiological studies, and (3) several meta-analyses (combined statistical analyses of the data from several different studies).

Cohort studies found that *H. pylori*-infected individuals were more likely to develop stomach cancer than were uninfected individuals (IARC 2012). These studies followed subjects with and without *H. pylori* infection for 4 to 10 years. Depending on the study, the subjects were either asymptomatic or had various types of stomach disease and were enrolled in various types of screening programs. Numerous nested case-control studies (case-control analyses conducted within cohorts of subjects), with follow-up times up to 15 years, provided evidence that the increased risk was specifically for non-cardia gastric cancer (IARC 2012). A pooled analysis of 12 of these nested case-control studies, which included 762 case subjects and 2,250 control subjects, matched to the case subjects by age, sex, and date of sample collection for *H. pylori* testing, found a risk factor of 2.97 (95% confidence interval [CI] = 2.34 to 3.77) for non-cardia gastric cancer and *H. pylori* infection (Helicobacter Cancer Collaborative Group 2001). The highest risk was for subjects followed for a longer time after enrollment (odds ratio [OR] = 5.93, 95% CI = 3.41 to 10.30 for ≥ 10 years of follow-up, compared with OR = 2.39, 95% CI = 1.82 to 3.12 for < 10 years of follow-up).

Similar findings of an excess risk of non-cardia gastric cancer were reported in a meta-analysis of data from eight studies (Huang et al. 2003). Nested case-control studies that either were published after the 2001 pooled analysis or had accrued more cases since the 2001 pooled analysis also found significantly elevated risks for non-cardia gastric cancer, confirming the association with *H. pylori* infection.

Most epidemiological studies measured *H. pylori* infection status by the presence of antibodies to *H. pylori* (i.e., seropositivity). Higher risks for non-cardia gastric cancer (increased by over tenfold) were found when *H. pylori* seropositivity was measured by a more sensitive assay (immunoblot, rather than the ELISA method typically used) (González et al. 2012; Mitchell et al. 2008; Simán et al. 2007). In most studies that looked at infection with various strains of *H. pylori*, higher risks were found for infection with strains that produced CagA than for infection with CagA-negative strains. A meta-analysis of data on *H. pylori*-positive cases from nine studies found that CagA seropositivity approximately doubled the risk of non-cardia gastric cancer over that due to *H. pylori* infection alone (Huang et al. 2003). Some studies have evaluated gastric cancer risk for specific CagA variants (type and number of EPIYA motifs, see Properties); e.g., a single EPIYA-D motif was associated with increased gastric cancer in studies in Asia, whereas multiple EPIYA-C motifs were associated with increased gastric cancer risk in studies in the United States and Europe (Li et al. 2017).

Some studies found a higher risk of stomach cancer among *H. pylori*-infected individuals who smoked or who consumed salted, smoked, processed foods, or red meat, and a lower risk among those with diets high in vegetables or intake of vitamins, suggesting that these exposures (diet or types of food) may be co-factors for *H. pylori*-induced stomach cancer (Epplein et al. 2014; IARC 2012). Several studies controlled for known risk factors for stomach cancer, and increased risks were found in studies in various geographical locations, which increases confidence that the elevated risks observed in these studies are not explained by bias, chance, or confounding.

Evidence for a role of *H. pylori* in cardia gastric cancer is less clear and may be restricted to specific subtypes of cardia gastric cancer. Neither the *Helicobacter* Cancer Collaborative Group pooled analysis of nested case-control studies (274 cases and 827 controls) nor the meta-analysis by Huang et al. (2003) of 16 published studies found an excess risk of cardia gastric cancer and *H. pylori* infection. However, a meta-analysis of all types of studies (primarily case-control studies) found that *H. pylori* infection increased the risk of cardia gastric cancer in high-risk countries (adjusted relative risk [RR] = 1.59, 95% CI = 1.03 to 1.45; 11 studies) but not in low-risk countries (RR = 0.80, 95% CI = 0.63 to 1.02; 14 studies) (Cavaleiro-Pinto et al. 2011). The differences in the risk patterns might be due to different subtypes of cardia gastric cancer or inclusion of adenocarcinoma of the esophagus or the gastroesophageal junction with cardia gastric cancer; however, few studies have addressed these anatomical distinctions (Malfertheiner et al. 2017).

Gastric MALT Lymphoma

Evidence that *H. pylori* causes gastric MALT lymphoma comes primarily from 16 intervention (non-controlled) studies [as reviewed by IARC (2012)], which found that eradication of *H. pylori* infection in gastric MALT lymphoma patients resulted in high rates (62% to 100%) of complete remission of the cancer. A pooled analysis of patients with gastric MALT lymphoma from 32 studies found that remission occurred in approximately 78% of the patients who were cured of *H. pylori* infection (Zullo et al. 2010a). Because of the rarity of this cancer, the number of observations is limited. Two small case-control analyses (a prospective nested case-control study and a hospital-based case-control study) found a positive association between *H. pylori* infection and gastric MALT lymphoma, which provides additional support for a causal relationship [Parsonnet et al. (1994) and de Sanjose et al. (2004), as cited by IARC (2012)].

2.4.2. Cancer Studies in Experimental Animals

H. pylori infection (orally administered by gavage) caused malignant tumors in two different types of stomach tissue in rodents. Importantly, the types of cancer observed in animals infected with *H. pylori*—gastric tumors and gastric lymphoma—are similar to those linked with *H. pylori* infection in humans. Some of these animal models are thought to mimic tumor progression in humans, as they also show similar types of *H. pylori*-induced gastric lesions.

H. pylori infection increased the incidences of malignant stomach tumors (mainly adenocarcinoma and some carcinoid) (1) in Mongolian gerbils in some, but not all, studies and (2) in transgenic (genetically altered) mice. Differences in the findings in gerbils may be due to differences in the *H. pylori* strain, gerbil strain, dose, and/or duration of exposure. A gerbil-adapted strain of *H. pylori* (derived from a human gastric ulcer strain) increased the incidence of malignant stomach tumors in Mongolian gerbils as early as 8 to 12 weeks after infection [Franco et al. (2005); Franco et al. (2008); and Romero-Gallo et al. (2008), as cited by IARC (2012)]. In general, findings in gerbils infected with other *H. pylori* strains were mixed; positive findings were more common in studies of longer duration, conducted in Asia, or using higher doses. IARC (2012) noted that the genetic background of the Mongolian gerbils may have evolved differently among colonies established in different geographic locations and that the pathology grading varied among studies. *H. pylori* infection caused gastric carcinoma in several studies in INS-GAS transgenic mice, which have been genetically modified to produce more gastrin (a peptide that increases the secretion of gastric acid). In studies of other types of transgenic mice (TGF- β - or p27-deficient mice, which have increased susceptibility to carcinogens), *H. pylori* infection increased the incidence of combined gastric dysplasia (a precancerous lesion) and carcinoma (IARC 2012). Two studies, one in Mongolian gerbils [Romero-Gallo et al. (2008), as cited by IARC (2012)] and the other in transgenic mice [Lee et al. (2008), as cited by IARC (2012)], found that *H. pylori* eradication therapy, when given early, inhibited the development of malignant stomach tumors (adenocarcinoma), which increases confidence that *H. pylori* causes stomach cancer in experimental animals.

There is strong evidence that *H. pylori* given in combination with other carcinogens (*N*-methyl-*N*-nitrosourea [MNU], *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, or ethylnitronitrosoguanidine) increased the incidences of stomach tumors over those in rodents (IARC 2012) and non-human primates (Liu et al. 2009) exposed only to the other carcinogens. Early *H. pylori* eradication therapy reduced the incidence of stomach tumors (adenocarcinoma) induced by combined administration of *H. pylori* and MNU [Nozaki et al. (2002), as cited by IARC (2012)]. The addition of a high-salt diet also increased the incidence of stomach tumors in *H. pylori*-infected gerbils.

H. pylori infection caused gastric lymphoma in two different strains of inbred mice [Wang et al. (2003), as cited by IARC (2012)] and in neonatal mice that had had their thymus glands removed (Fukui et al. 2004). In the latter study, all of the mice developed gastric MALT lymphoma by the age of 12 months.

2.4.3. Mechanisms of Carcinogenesis and Other Relevant Data

The mechanisms by which *H. pylori* causes stomach cancer are complex and involve many different factors. They involve interactions between (1) direct effects of the toxic action of *H. pylori* virulence factors (e.g., the effects of CagA, VacA, and outer inflammatory protein),

(2) indirect effects due to modification of the infected individual's inflammatory responses to chronic *H. pylori* infection, which can be influenced by the genes regulating immune processes and by lifestyle and dietary habits, and (3) changes in acid secretion in the stomach. Collectively, this information may help to explain why only a small fraction of *H. pylori*-infected individuals (10% in high-risk countries and 1% to 3% in other countries) develop stomach cancer (Balakrishnan et al. 2017; IARC 2012; Servetas et al. 2016).

H. pylori infection is usually acquired in childhood and can cause inflammation or irritation of the lining (mucosa) of the stomach (chronic infection, or gastritis). This gastritis is associated with recruitment of various types of immune cells (e.g., neutrophils and lymphocytes). Progression to more serious stomach diseases, such as ulcers, MALT lymphoma, and non-cardia gastric cancer, occurs as the infected individual grows older, and it depends on factors specific to the infected individual and to the bacterium, as well as on the acidity of the stomach environment. Chronic inflammation of the stomach mucosa (chronic atrophic gastritis, occurring mainly in the corpus of the stomach) is associated with changes in the types of tissues and cells in the stomach (IARC 2012).

Most individuals infected with *H. pylori* do not develop symptoms; however, in some people, atrophic gastritis can progress to stomach ulcers or precancerous lesions (e.g., intestinal metaplasia and dysplasia), which can progress to stomach cancer (adenocarcinoma). Several studies provided evidence that progression of gastric lesions increased the risk of *H. pylori*-induced gastric cancer. A cohort study of middle-aged Japanese men found that the risk of *H. pylori*-induced gastric cancer relative to that in uninfected men increased with increasing severity of *H. pylori* lesions (i.e., from non-chronic atrophic gastritis to chronic atrophic gastritis to metaplastic gastritis (Ohata et al. 2004; Yoshida et al. 2014). A German cohort study found that having chronic atrophic gastritis was associated with a fivefold increase in the risk of non-cardia gastric cancer (Chen et al. 2016). In this study, serological biomarkers were used to assess the stages of gastritis.

In infected individuals with higher acid secretion, gastritis is more likely to develop in the lower part of the stomach (antrum-predominant gastritis) and can progress to ulcers in the small intestine (duodenal ulcers). Gastric MALT lymphoma can develop from gastritis in any part of the stomach (pangastritis) (Conteduca et al. 2013; IARC 2012; Ishaq and Nunn 2015; Testerman and Morris 2014).

H. pylori-induced chronic inflammation can lead to oxidative stress, aberrant expression of genes (e.g., suppression of the expression of some genes and enhancement of the expression of others, primarily via the process of aberrant DNA methylation), and disruption of enzymes involved in repairing DNA damage. This results in increased DNA damage in cells of the stomach lining (epithelial cells) and can result in mutation and genetic instability (Graham 2015; Maeda et al. 2017; Servetas et al. 2016). In addition, *H. pylori* either directly or indirectly (e.g., via inflammation) targets biological pathways involved in cell turnover, survival, and proliferation (e.g., by inhibiting tumor-suppressor genes). *H. pylori* also initiates changes in the characteristics of stomach epithelial cells (known as the “epithelial to mesenchymal transition”) that enable the cells to proliferate as cancer cells do (Servetas et al. 2016).

Some of these biological effects vary depending on virulence factors, the production of which can differ among *H. pylori* strains. For example, some *H. pylori* strains (such as CagA-positive

strains) can induce a high degree of chronic inflammation (Figura et al. 2016). Moreover, studies in animals and cells have shown that CagA is an oncoprotein (i.e., when the gene is transferred into cells or animals, it causes gastric cells to proliferate and develop into tumors) (Wang et al. 2015). Virulence factors in *H. pylori* strains vary geographically, which may help to explain geographical patterns of stomach cancer risk (Wang et al. 2015; Yamaoka and Graham 2014). As discussed above, cancer risks are higher for CagA-positive *H. pylori* infection than for CagA-negative infection. A German cohort study (Chen et al. 2016) found that people with *H. pylori* CagA-positive infection who had markers in their blood for chronic atrophic gastritis had a much higher risk of developing non-cardia gastric cancer (hazard ratio [HR] = 32.4, 95% CI = 7.6 to 137.6) than did people without these two risk factors. These biological effects (chronic inflammation, changes in gene expression, mutations, genomic instability, and cellular proliferation) are associated with carcinogenesis.

2.4.4. NTP's Listing Recommendation

Helicobacter pylori (chronic infection) is *known to be a human carcinogen* based on sufficient evidence of carcinogenicity from studies in humans. This conclusion is based on epidemiological studies showing that *H. pylori* infection causes stomach cancer (especially non-cardia gastric cancer) and a specific type of lymphoma in the stomach (gastric MALT lymphoma).

H. pylori is estimated to cause 89% of non-cardia gastric cancer and 92% to 98% of all gastric MALT lymphoma cases. It is responsible for approximately 780,000 cancer cases (primarily gastric cancer) worldwide each year, accounting for 6.2% of all cancer cases (Plummer et al. 2015; Testerman and Morris 2014). Mechanistic and toxicological data indicate that chronic infection of the stomach with *H. pylori* is required for carcinogenicity, and they demonstrate the biological plausibility of its carcinogenicity. Studies in experimental animals indicate that *H. pylori* induces types of tumors similar to those found in humans: adenocarcinoma and lymphoma of the stomach.

2.5. Regulations

2.5.1. Department of Transportation (DOT)

Infectious substances are considered hazardous materials, and special requirements have been set for marking, labeling, and transporting these materials.

2.5.2. Food and Drug Administration (FDA, an Agency of Health and Human Services)

Helicobacter pylori is listed as a qualifying pathogen having the potential to pose a serious threat to public health under the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act (FDASIA). GAIN is intended to encourage development of new antibacterial and antifungal drugs for the treatment of serious or life-threatening infections.

2.5.3. Occupational Safety and Health Administration (OSHA)

First-aid training program trainees must have adequate instruction in the value of universal precautions for minimizing exposure to blood and other potentially infectious material.

3. Prevention of *H. pylori*-associated Cancer

Stomach cancer is the fifth most common cancer worldwide, with around 1.3 million new cases occurring annually, and the third most common cause of death from cancer—it is estimated that over 800,000 people died of stomach cancer worldwide in 2015 (Fitzmaurice et al. 2017). An estimated 73% of all stomach-cancer cases are non-cardia gastric cancer (Colquhoun et al. 2015). Worldwide, 70% of all stomach-cancer cases occur in low-income countries. In low-risk areas, such as the United States, Europe, Australia, and New Zealand, the incidence of and mortality from stomach cancer show disparities, with minority, indigenous, and immigrant populations at higher risk (Balakrishnan et al. 2017; Epplein et al. 2011; SEER 2018; Taylor et al. 2014). In the United States, stomach cancer accounts for 1.7% of all new cancer cases, but some minority populations have a 40% to 50% higher risk (Bjorkman 2017; SEER 2018). In addition to disparities by geography and race, stomach-cancer incidence and mortality are higher in men than women; worldwide, the estimated age-standardized incidence rate in men is twice that in women (Forman and Sierra 2014; Herrero et al. 2014). Overall stomach-cancer incidence has decreased in recent years, by approximately 2% per year; however, recent evidence suggests it may be increasing in younger populations (Anderson et al. 2018). The estimated global burden of the disease is expected to increase in the next 10 to 15 years, primarily as a result of population growth and aging [Ferlay et al. (2013), as cited by IARC (2014)].

H. pylori infection has been established as a cause for non-cardia gastric cancer and gastric MALT lymphoma (IARC (2012); see Section 2) and may account for up to 6.2% of all cancer deaths worldwide (Plummer et al. 2015). Calculated population attributable fractions range from 75% to 89%, indicating that a large majority of these cancer cases could be avoided if *H. pylori* exposure were eliminated (de Martel et al. 2012; Plummer et al. 2015; Song and Zhou 2015).

This section provides an overview of the state of science for prevention of *H. pylori*-induced cancer, the cost-effectiveness of this prevention, issues and concerns for large-scale prevention programs, and current national and regional policies for stomach cancer prevention.

3.1. Prevention of *H. pylori*-induced Cancers: State of the Science

Screening and treatment of *H. pylori*-infected individuals show promise as a method for the prevention of stomach cancer. Over the past 20 years, numerous studies have been conducted on the effectiveness of screening and treatment methods. Three screening methods and two types of treatment have been evaluated (see Section 3.1.1). The benefits of *H. pylori* eradication have been evaluated in 10 randomized controlled trials and at least 16 cohorts. These studies support eradication of *H. pylori* for the prevention of stomach cancer, and recent meta-analyses have confirmed these findings (see Section 3.1.2). Moreover, several economic analyses have determined that screening and treatment of *H. pylori* is cost-effective as a prevention method (see Section 3.1.3). Several issues and concerns relevant to the implementation of large-scale eradication efforts must be taken into account. These include antibiotic resistance, the likelihood of *H. pylori* reinfection, the possible inverse relationship between *H. pylori* infection and some other gastric illnesses, the presence of atrophic damage at the time of eradication, and the need to tailor treatment programs to specific geographic regions (see Section 3.1.4).

Other methods of prevention of *H. pylori*-induced cancer include preventing the spread of *H. pylori* and developing a vaccine (see Section 2 for a discussion on the spread of *H. pylori*).

3.1.1. Screening for and Treatment of *H. pylori* Infection

H. pylori screening and treatment have been identified as candidates for population-level intervention programs in high-prevalence areas, supported by several cost-benefit analyses; however, additional data are needed. Several methods exist for *H. pylori* population screening, including serology tests for *H. pylori* antibodies, a stool antigen test, and a urea breath test. Stool antigen and urea breath tests are more expensive and may be harder to implement at a population level. *H. pylori* serological tests (for antibodies) detect both past and present infections, and therefore are not useful for determining the efficacy of *H. pylori* treatment (Moayyedi 2014) (see Section 2 for more details on detection methods).

Treatment of *H. pylori* infection often can achieve a high rate of eradication. The most common treatment is a standard triple therapy, which includes a PPI, clarithromycin, and either amoxicillin or metronidazole antibiotics given for 1 to 2 weeks. This PPI triple therapy is relatively low-cost and widely available. Early reports suggested that this treatment resulted in eradication rates of over 90%; however, rates more recently have fallen well below 80%. In some locations in Europe, the eradication rate for the standard PPI triple therapy is as low as 25% to 60%. This variability in effectiveness is likely due to the rise in antibiotic resistance, specifically to clarithromycin. In many parts of the world, clarithromycin resistance is so high that the clarithromycin-based PPI triple therapy is not recommended as the first-line treatment. Methods to improve the effectiveness of the PPI triple therapy have been proposed, such as increasing the dose by increasing the frequency of treatment, using second-generation PPIs, or increasing treatment duration [reviewed by Gisbert and Greenberg (2014)]. Another treatment currently recommended as a first-line therapy (concomitant therapy) adds metronidazole or nitroimidazole to the standard PPI treatment (Chey et al. 2017).

Another low-cost therapy (bismuth-containing quadruple therapy) combines bismuth salts, tetracycline, a PPI, and metronidazole for 14 days, with a reported eradication rate of over 80% to 90%. Bismuth-containing quadruple therapy is now recommended as the first-line treatment in areas of high clarithromycin resistance, while standard PPI triple therapy may be used in areas of low resistance. Although metronidazole resistance is high worldwide, the clinical impact of this resistance is low, and the quadruple therapy is effective when dose and duration are increased. Additional studies are needed on the effectiveness of bismuth-containing quadruple therapy as a first-line treatment. The unavailability of bismuth and tetracycline in many areas also must be considered for any population-level intervention programs. Because antibiotic resistance varies within populations, programs should use treatment regimens that have proven reliably effective in the target population and area, or methods based on the observed pattern of resistance [reviewed by Gisbert and Greenberg (2014) and Herrero et al. (2014)].

3.1.2. Efficacy and Effectiveness of *H. pylori* Eradication in Preventing Stomach Cancer

Gastric Cancer

Since 1997, a number of cohort studies and randomized controlled trials have been conducted to determine the efficacy and effectiveness of *H. pylori* eradication therapy in preventing gastric

cancer. These studies looked at the effectiveness of eradication among individuals who had never had stomach cancer (primary prevention) and among patients with previous endoscopic resection of early gastric cancer (secondary prevention, sometimes referred to as tertiary prevention). The cohort studies were generally conducted in Japan and Korea, with one study each in Taiwan and Finland, and enrolled between 50 and 8,000 participants, with follow-up times ranging from 2 to 10 years.

Since 2000, six randomized controlled trials have investigated the primary prevention of gastric cancer following *H. pylori* eradication therapy. These trials have been primarily in China, with one each in Colombia (Correa et al. 2000) and Japan (Saito et al. 2005); follow-up times ranged from 3 to 14.7 years. An additional three trials, one in Japan (Fukase et al. 2008) and two in South Korea (Choi et al. 2018; Choi et al. 2014b), looked at the efficacy of *H. pylori* eradication for the secondary prevention of gastric cancer, with follow-up times of approximately 3 to 6 years.

Taken together, the nine trials demonstrated the partial effectiveness of *H. pylori* eradication therapy in reducing the incidence of gastric cancer. These studies generally had a large number of total participants, but many had small numbers of cases in both study arms. Only two of the nine studies had follow-up times exceeding 10 years, which may explain the lack of significant findings in several studies. Furthermore, all of these trials used the standard PPI triple therapy for eradication, and not the bismuth-containing quadruple therapy, which may be more effective in areas with high levels of clarithromycin resistance. Finally, all but one trial took place in eastern Asia, which may limit the generalizability of the results to other populations. The results of the randomized controlled trials are summarized in Table 3-1. Additional data will be provided by several ongoing trials, as well as long-term follow-up of the current studies. Additional data on prevention efficacy may provide additional support for large-scale eradication programs.

Table 3-1. Randomized Controlled Trials of *H. pylori* Eradication and the Incidence of Gastric Cancer

References Geographic Location	Study Population No. of Subjects ^a Follow-up Duration	End Points	RR, HR, or OR (95% CI); No. of Cases ^a
Individuals without gastric cancer			
Correa et al. (2000) Colombia ^b	Asymptomatic men and women aged 29–69 with advanced gastric lesions (CAG, IM, and DYS); enrolled 1991 491/485 6 years	Gastric cancer IM regression IM progression	[1.48 (0.25–8.83); 3/2 cases] ^c 3.1 (1.0–9.3) 0.4 (0.2–0.9)
Wong et al. (2004) China	Asymptomatic men and women aged 35–65 with mixed gastric lesions; enrolled 1994 817/813 7.5 years	Gastric cancer All subjects Baseline precancerous lesions No (62%) Yes (CAG, IM, DYS)	0.63 (0.24–1.62); 7/11 p = 0.02; 0/6 p = 0.67; 7/5

RoC Monograph on *Helicobacter pylori* (Chronic Infection)

References Geographic Location	Study Population No. of Subjects ^a Follow-up Duration	End Points	RR, HR, or OR (95% CI); No. of Cases ^a
Saito et al. (2005) Japan	Asymptomatic men and women aged 20–59 379/313 4 years	Gastric cancer	0.55 (0.09–3.27); 2/3
Zhou et al. (2014) Leung et al. (2004) China	Asymptomatic men and women aged 35–75 with mixed gastric lesions; enrolled 1996 276/276 (2014); 295/292 (2004) 10 years (2014) 5 years (2004)	Gastric cancer 2014 (all) 2014 (no CAG) 2004 study IM progression 2014 2004	[0.29 (0.06–1.36)] ^d ; 2/7 0.00 (0.00–0.81); 0/6 [0.66 (0.18–2.36)]; 4/6 0.85 (0.78–0.92); NR 0.63 (0.43–0.93); 104/126
Ma et al. (2012) You et al. (2006) (7-year follow up) Li et al. (2014) (subgroup analyses) China	Asymptomatic men and women aged 35–64 with mixed gastric lesions; enrolled 1994–1995 (Shandong Intervention Trial) 1,130/1,128 14.7 years	All subjects Incidence Mortality Age ≥ 55 Incidence Mortality Baseline lesions Less severe (includes CAG) IM and DYS	0.61 (0.39–0.96); 34/52 0.68 (0.36–1.29); 16/23 0.36 (0.17–0.79); 10/24 0.26 (0.09–0.79); 4/15 1.08 (0.31–3.81); 5/5 0.56 (0.34–0.91); 28/46
Wong et al. (2012) China	Asymptomatic men and women aged 35–64 with advanced gastric lesions (CAG or greater) enrolled 2002 255/285 4 years	Gastric cancer Regression Progression	[3.04 (0.32–28.99)] ^e ; 3/1 2.19 (1.32–3.64); 96/82 1.08 (0.58–2.02); 30/50
Gastric cancer patients^f			
Fukase et al. (2008) Japan	Men and women aged 20–79 with early gastric cancer resection; enrolled 2001–2003 (secondary prevention) 272/272 3 years	Secondary gastric cancer	0.35 (0.16–0.78); 9/24

References Geographic Location	Study Population No. of Subjects ^a Follow-up Duration	End Points	RR, HR, or OR (95% CI); No. of Cases ^a
Choi et al. (2014b) South Korea	Men and women aged 20–75 with early gastric cancer resection; enrolled 2005–2011 (secondary prevention) 444/457 2.6–93.3 months (Median = 38 months)	Secondary gastric cancer	[0.61 (0.28–1.31)] ^d ; 10/17 (p = 0.15 by log rank)
Choi et al. (2018) South Korea	Men and women aged 18–75 with early gastric cancer resection; enrolled 2003–2013 (secondary prevention) 194/202 Median = 5.9 years, Maximum = 12.9 years	Secondary gastric cancer	0.50 (0.26–0.94); 14/27 p = 0.03

CAG = chronic atrophic gastritis; DYS = dysplasia; HR = hazard ratio; IM = intestinal metaplasia; IRQ = interquartile range; OR = odds ratio; RR = relative risk.

^aTreatment/placebo.

^bSubjects were followed after the intervention, and patients in the placebo group were offered treatment (Mera et al. 2005; Mera et al. 2017).

^cEffect estimate calculated by Ford et al. (2014) meta-analysis.

^dEffect estimate calculated by Lee et al. (2016) meta-analysis.

^eEffect estimate calculated by Ford et al. (2014) meta-analysis. The authors did not evaluate gastric cancer, because seven of the nine cancer cases across several treatment groups occurred during the treatment period.

^fPatients with previous endoscopic resection of early gastric cancer.

The most informative studies were two large trials in China that evaluated primary prevention of gastric cancer. The Shandong Intervention Trial (Li et al. 2014; Ma et al. 2012; You et al. 2006) enrolled and randomized 2,258 *H. pylori*-seropositive subjects who were followed for 14.7 years, resulting in 34 cancer cases in the intervention group and 52 in the placebo group (OR = 0.61, 95% CI = 0.38 to 0.96). The next-largest trial, also conducted in China, enrolled 1,630 *H. pylori*-seropositive participants who were followed for 7.5 years. A total of 7 cancer cases were seen in the intervention group and 11 in the placebo group (HR = 0.63, 95% CI = 0.24 to 1.52) (Wong et al. 2004). These studies stratified by the type of gastric lesion at baseline but defined the lesion categories differently. The Shandong Intervention Trial grouped chronic atrophic gastritis with less severe lesions and found that *H. pylori* eradication was effective in preventing gastric cancer among participants with precancerous lesions (intestinal metaplasia and dysplasia) at baseline, but not among patients with less severe lesions; however, few cases of gastric cancer were seen in either treatment arm (intervention or placebo) among the patients with less severe lesions. In contrast, Wong et al. (2004) grouped chronic atrophic gastritis with the precancerous lesions and found that *H. pylori* eradication was effective only among patients with less severe lesions (see Table 3-1).

The additional four trials of primary prevention, two in China (Wong et al. 2012; Zhou et al. 2014) and one each in Colombia (Correa et al. 2000) and Japan (Saito et al. 2005), had a combined total of 10 gastric cancer cases in the intervention groups and 13 in the placebo groups. Two smaller studies lacked sufficient statistical power to evaluate gastric cancer

incidence, but reported that *H. pylori* treatment was effective in promoting the regression of histological gastric lesions (Correa et al. 2000; Zhou et al. 2014). Wong et al. (2012) did not evaluate the effect of treatment on gastric cancer incidence, because seven of the nine cancer cases (across several treatment options, such as COX 2 inhibitor treatment) occurred during the treatment period.

When all six randomized controlled trials of primary prevention were included in a meta-analysis, the risk ratio was 0.66 (95% CI = 0.46 to 0.95), indicating a beneficial effect of *H. pylori* eradication therapy (Ford et al. 2014). It should be noted that these results were heavily weighted by the results in the Shandong Intervention Trial. Ford et al. (2014) also conducted a meta-analysis evaluating cancer mortality and found a non-statistically significant decrease in mortality in the intervention group (RR = 0.67, 95% CI = 0.40 to 1.11); the analysis included 24 deaths in the intervention groups and 36 in the placebo groups (Ford et al. 2014).

Three trials evaluating prevention of metachronous gastric cancer or “secondary prevention” (in Japan and South Korea) found a lower risk of new cancer in the *H. pylori* intervention group than in the control group (Choi et al. 2018; Choi et al. 2014b; Fukase et al. 2008). The findings were statistically significant in the Japanese study and in the Choi et al. (2018) study (see Table 3-1); additionally, when the results of the two earliest studies (Choi et al. 2014b; Fukase et al. 2008) were combined in a meta-analysis, a protective effect of eradication therapy was seen (RR = 0.47, 95% CI = 0.28 to 0.80) (Wald 2014).

Meta-analyses that pooled the results of cohort studies or of cohort studies and randomized controlled trials combined found results similar to those of the meta-analyses of the trials. An analysis of eight primary-prevention cohort studies reported a relative risk of 0.46 (95% CI = 0.32 to 0.66) (Doorakkers et al. 2016). A meta-analysis of both trials and cohort studies found relative risks of 0.62 (95% CI = 0.49 to 0.79) for primary prevention (six trials and eight cohorts) and 0.46 (95% CI = 0.35 to 0.60) for secondary prevention of metachronous gastric cancer (two trials and eight cohorts) (Lee et al. 2016). Another secondary-prevention meta-analysis (Yoon et al. 2014) found a relative risk of 0.42 (95% CI = 0.32 to 0.56) in a pooled analysis of 13 trials or cohort studies. Additional meta-analyses that combined both primary- and secondary-prevention studies (Chen et al. 2016; Hernández et al. 2014; Lee et al. 2016) were considered to be less informative. The results of these meta-analyses are summarized in Table 3-2. Other meta-analysis publications were identified but are not included in Table 3-2 because they included multiple publications of the same study in the analysis or included studies that did not evaluate efficacy or effectiveness in cancer prevention.

Table 3-2. Meta-analyses of Randomized Controlled Trials and Cohort Studies Investigating the Effectiveness of *H. pylori* Eradication in Reducing Gastric Cancer Incidence

Reference	Type of Study (No. of Studies)	Exposure Group (No. of Studies)	Risk Estimate	Heterogeneity
Studies on individuals without gastric cancer				
Ford et al. (2014)	Trial (6)	Type of outcome		
		Incidence (6)	0.66 (0.46–0.95)	I ² = 0%; p = 0.60
		Mortality (3)	0.67 (0.40–1.11)	I ² = 0%; p = 0.90
		Pre-neoplastic lesions present		
		No (2)	0.42 (0.02–7.69)	
		Yes (4)	0.86 (0.47–1.59)	
		Mixed (2)	0.38 (0.12–1.23)	
Doorakkers et al. (2016)	Cohort (8)	Overall analysis	0.46 (0.32–0.66)	I ² = 32.3%; p = 0.17
		Adjusted for follow-up and confounding (4)	0.46 (0.29–0.72)	I ² = 44.4%; p = 0.15
Studies on gastric cancer patients ^a				
Yoon et al. (2014) ^b	Trial (2)	Trial and prospective cohort (3)	0.39 (0.20–0.75)	I ² = 24.7%; p = 0.27 Outcome is metachronous gastric cancer
	Cohort (8)			
	Other observational (2)			
Combined studies of cancer and cancer-free patients				
Chen et al. (2016)	Trial (8)	All studies	0.64 (0.48–0.85)	I ² = 32.3%; p = 0.93
		Baseline diagnosis		
		Non-atrophic gastritis/gastritis	0.25 (0.08–0.81)	
		IM/DYS	0.88 (0.59–1.31)	
Hernández et al. (2014)	Trial (7)	Overall five studies	0.57 (0.42–0.79)	I ² = 0%; p = 0.48 ^c
Lee et al. (2016)	Trial (8)	All studies	0.54 (0.46–0.65)	I ² = 0.0%; p = 0.67
	Cohort (16)	Trial	0.60 (0.44–0.81)	
		Cohort	0.52 (0.41–0.64)	
		Primary intervention	0.62 (0.49–0.79)	
		Secondary intervention	0.46 (0.35–0.60)	
		Baseline incidence of gastric cancer (tertiles)		
		Lowest	0.80 (0.56–1.15)	
		Middle	0.49 (0.38–0.64)	
		Highest	0.45 (0.32–0.64)	

CAG = chronic atrophic gastritis; DYS = dysplasia; IM = intestinal metaplasia.

^aPatients with previous endoscopic resection of early gastric cancer.^bBecause the meta-analysis of all studies included those that were not analytic studies, the results of that analysis are not included in the table.^cDoes not include Wong et al. (2012), Saito et al. (2005), or Choi et al. (2014b).

Several additional planned or ongoing studies will investigate the efficacy of *H. pylori* eradication in reducing the incidence of gastric cancer. A large-scale study in Baltic and Eastern European countries (the GISTAR study), which has recently begun recruitment, aims to recruit 30,000 men and women aged 40 to 64 and follow them for 15 years (Leja et al. 2017; Leja et al. 2014). A study in South Korea that has also recently begun recruitment plans to recruit 11,000 men and women aged 40 to 65 who are invited to participate in the national gastric cancer screening program. Those found to be infected with *H. pylori* will be randomized into the eradication study and followed for at least 10 years (Choi et al. 2014a; Park et al. 2017). A third ongoing study in the United Kingdom (the *H. pylori* Screening Study) recruited participants between 1997 and 2006. Although this is not an eradication study, those screened for *H. pylori* who tested positive were treated. All participants will be followed for 15 to 20 years (Wald 2014). Although not a placebo-controlled trial, a large study in China will compare a high-dose treatment with a low-dose treatment in 180,000 participants followed for at least 7 years. Initial eradication rates in the high-dose group were approximately 73% (Pan et al. 2016).

Gastric MALT Lymphoma

Because MALT lymphoma is a rare cancer, no randomized controlled trials have assessed the efficacy of *H. pylori* eradication therapy for its prevention and treatment; however, efficacy has been assessed in numerous observational studies. In a meta-analysis of 32 observational studies with 1,408 gastric MALT lymphoma patients, Zullo et al. (2009) found that *H. pylori* eradication treatment resulted in an overall remission rate of 77.5% (95% CI = 75.3% to 79.7%). Remission rates were higher for Stage 1 than Stage 2 lymphoma (75.3% vs. 55.6%), but treatment was effective at both cancer stages. Median follow-up times for these studies ranged from 1 to 5 years. Recently, long-term follow-up studies of gastric MALT lymphoma patients receiving *H. pylori* eradication therapy have shown remission in up to 80% of cases, with 80% of these individuals remaining disease-free after 10 years (Fischbach 2014; Wündisch et al. 2012).

3.1.3. Cost-benefit Analyses Studies

Numerous economic models in numerous geographic locations, including both low- and high-prevalence countries, have been published that evaluated whether *H. pylori* screening and treatment are cost-effective measures for the prevention of stomach cancer in a variety of populations. Two systematic reviews published in 2013 (Areia et al. 2013; Lansdorpf-Vogelaar and Sharp 2013) reviewed 12 cost-effectiveness studies on *H. pylori* screening and treatment in the general population, including four studies each from North America, Europe, and Asia. Areia et al. (2013) also reviewed one South Korean cost-effectiveness study on *H. pylori* eradication after endoscopic removal of gastric cancer. The IARC working group on *H. pylori* eradication reviewed nine economic studies (Moayyedi 2014). Several new cost-effectiveness studies of screening and treatment have been published since these 2013 reviews. These newer studies were conducted in the United States (Yeh et al. 2016), Australia (Schulz et al. 2014), New Zealand (Teng et al. 2017), Taiwan (Cheng et al. 2015), and Hong Kong (Wong et al. 2014). Studies found *H. pylori* screening and treatment to be cost-effective based on a threshold of \$50,000 per life-year saved, especially for high-risk populations. Importantly, the findings in many studies were robust to differences in *H. pylori* prevalence and patient gender and ethnicity (Lansdorpf-Vogelaar and Sharp 2013). Most studies assumed 30% effectiveness of *H. pylori* eradication in reducing gastric cancer incidence; however, sensitivity analyses found that *H. pylori* eradication

would still be cost-effective if the effectiveness of *H. pylori* eradication in reducing stomach cancer incidence were as low as 15% (Lansdorp-Vogelaar and Sharp 2013).

Factors that may influence the cost-effectiveness of *H. pylori* screening and treatment include screening methods, type of *H. pylori* therapy, and population characteristics such as age, race, or ethnicity, migrant status, and geographic region. Most general-population studies in both high- and low-prevalence countries evaluated serology screening (the most available test) and found it to be cost-effective [reviewed by Areia et al. (2013); Cheng et al. (2015); Lansdorp-Vogelaar and Sharp (2013); Teng et al. (2017); Wong et al. (2014); Yeh et al. (2016)]. However, some studies reported that the stool antigen screening method, which has greater sensitivity and specificity, was more cost-effective than either serology or urea breath test screening [Xie et al. (2009), as cited by Areia et al. (2013); Schulz et al. (2014)]. Most cost-effectiveness studies considered only the standard PPI triple therapy; however, one study evaluated the bismuth-containing quadruple therapy and found it to be cost-effective as well [Xie et al. (2009), as cited by Moayyedi (2014)].

Population characteristics were also considered in the economic models. The overall conclusion of Areia et al. (2013) was that screening at or above age 50 was the most cost-effective; however, several Asian studies concluded that screening beginning at age 30 would be the most cost-effective [Cheng et al. (2015); Lee et al. (2007); and Yeh et al. (2009), as cited by Areia et al. (2013)]. The effect of age may depend on the population; for example, Teng et al. (2017) found that cost-effectiveness was highest for Māori participants aged 45 to 49 and non-Māori participants aged 60 to 64. A study in Australia (Schulz et al. 2014) found screening and treatment of immigrants and refugees from high-prevalence countries to be cost-effective, and concluded that it may be an effective strategy for reducing stomach cancer in these populations.

In an overview of 10 cost-effectiveness or cost-utility studies, Lansdorp-Vogelaar and Sharp (2013) concluded *H. pylori* screening and treatment was cost-effective, coming in well below the threshold of \$50,000 per life-year saved for the general population. In other, more recent, studies screening and treatment were found to be cost-effective only in populations at high-risk for gastric cancer, such as indigenous populations (Teng et al. 2017), or a subset of those at high risk, such as smokers (Yeh et al. 2016). In *H. pylori* high-prevalence countries, estimated costs ranged from \$200 to \$17,000 per life-year saved. The studies with the lowest assumed *H. pylori* prevalence had the highest cost per life-year saved, but eradication was still cost-effective. Likewise, studies reporting cost-effectiveness in low-prevalence countries also found screening and treatment to be cost-effective, ranging from \$10,000 to \$35,000 per life-year saved. While the cost-effectiveness estimates were, on average, higher in low-prevalence countries, they were still well below the threshold estimates (Lansdorp-Vogelaar and Sharp 2013).

In many of these studies, the cost-effectiveness threshold analyses considered only stomach cancer, and did not take into account the additional potential savings from *H. pylori* screening and treatment that could result from decreases in dyspepsia, ulcers, and other *H. pylori*-related disorders. The analyses also did not take into account the potential detrimental effects of increased antibiotic resistance or the potential reinfection rates, which have not been well studied (Hu et al. 2017; Lansdorp-Vogelaar and Sharp 2013). The IARC working group (IARC 2014) recommended that further studies should evaluate benefits using quality-adjusted life-years rather than life-years saved (Lansdorp-Vogelaar and Sharp 2013; Moayyedi 2014). Additional

economic cost-benefit analyses are needed from randomized controlled trials, especially in areas where the eradication programs are most likely to be implemented first.

3.1.4. Issues and Concerns

Although the potential for *H. pylori* eradication to prevent 30% to 40% of new cases of non-cardia gastric cancer has been demonstrated, no large-scale *H. pylori* eradication programs have been implemented; however, a few smaller, targeted eradication programs have been implemented regionally (see Section 3.2.2). This caution is partially due to concern about unintended consequences of such programs. Three major concerns about *H. pylori* eradication are the potential for increased bacterial resistance to antibiotics, a negative impact on the normal gastrointestinal flora found in the body, and the likelihood of reinfection with *H. pylori* after treatment. These concerns are compounded by the fact that many of the antibiotics used to treat *H. pylori* infection are commonly used to treat other serious infections. A recent European consensus report cautioned that use of commonly used antibiotics could create additional resistance selection on pathogens other than *H. pylori* (Malfertheiner et al. 2017). In addition, evidence suggests an inverse relationship between *H. pylori* infection and GERD and its complications, including Barrett's esophagus and esophageal adenocarcinoma [reviewed by Derakhshan et al. (2016); Parsonnet (2014)]. However, eradication does not appear to worsen pre-existing GERD (Zagari et al. 2015).

Reinfection with *H. pylori* has been observed to occur in more than 10% of those who were successfully treated in high prevalence areas, and reinfection rates increased as time since treatment increased (Hu et al. 2017; Morgan et al. 2013). In a recent review (Hu et al. 2017), reinfection rates ranged from 3.1% in countries with a very high human development index (HDI) to 11% in countries with a low HDI. Factors associated with reinfection included socioeconomic and sanitary conditions, as well as treatment adherence and study site, which was likely associated with regional antibiotic resistance, which suggests that recrudescence is a component of 1-year recurrence rates in many populations (Hu et al. 2017; Morgan et al. 2013).

Any eradication efforts should be tailored to the specific geographic area and target population, to guide the selection of appropriate antibiotic therapy and to develop better methods of treatment (Thung et al. 2016). All randomized controlled trials of eradication published to date were conducted in high-prevalence countries. However, both the short- and long-term effects of treatment programs will differ between regions with differing prevalence levels. Factors to consider in *H. pylori* eradication include the prevalence of *H. pylori* in the population, identification of the most appropriate population for screening (the general population or those showing symptoms of disease), the best age at which to begin screening, and the stage of disease at which eradication would be most effective. In high-prevalence regions, screening and treatment of the general population may be indicated, whereas in lower-prevalence countries with low-to-moderate risk of gastric cancer, integration of screening into existing prevention methods (such as colonoscopy screening) or screening those who show symptoms may be more effective (Lee et al. 2007). The optimal age for general screening and treatment programs may vary based on the prevalence of *H. pylori* in the population, and age should be taken into account (as discussed in Section 3.1.2).

The effectiveness of *H. pylori* eradication therapy in the prevention of stomach cancer may depend on the presence and severity of atrophic damage at the time of eradication (Sugano et al.

2015). *H. pylori* eradication therapy diminishes the inflammatory response and early treatment can help prevent the appearance of preneoplastic lesions. The optimal timing for stomach-cancer prevention may be before these preneoplastic conditions appear (Malfertheiner et al. 2017); however, *H. pylori* eradication may offer some benefits by reducing risk in the presence of preneoplastic conditions (Coelho et al. 2013; Malfertheiner et al. 2017). As mentioned in Section 3.1.2, the largest randomized controlled trial found that *H. pylori* eradication was effective in reducing cancer incidence among participants with precancerous lesions at baseline (Li et al. 2014).

3.2. Policies and Recommendations

Even though *H. pylori* is a treatable infection, and stomach cancer is one of the leading causes of cancer death worldwide, few national efforts at screening and prevention have been made (Section 3.2.2). There have been, however, numerous national and regional consensus statements on *H. pylori* screening and treatment in the prevention of *H. pylori*-induced cancer (Section 3.2.1).

3.2.1. National Consensus Recommendations for the Prevention of *H. pylori*-induced Cancer

Over the last 5 years, numerous publications have reported on national and regional consensus statements on *H. pylori* management. Typically, these statements are the result of a workshop of international, national, or regional experts who are charged with (1) reviewing the clinical and other relevant studies related to *H. pylori* management (e.g., diagnosis, treatment, and prevention) and (2) voting on the level of evidence (a grade reached according to specific guidelines) and the strength of recommendations for specific statements. Recommendations relevant to the prevention and treatment of *H. pylori*-induced cancer are summarized in Table 3-3. (Not included in the table are other recommendations, such as those for diagnosis and type of treatment.)

Table 3-3. Recommendations for Prevention of *H. pylori*-induced Cancer

Type of Recommendation	Population	Strength of the Association/Region	References
Screen and treat	General population	<i>Strong</i> : Should be considered for those under 35: Brazil (Third Brazilian Consensus)	Coelho et al. (2013)
		<i>Insufficient</i> : Chile (Chilean Society of Gastroenterology)	Torres et al. (2016)
		<i>Weak</i> : Asia (10 ASEAN countries); Bangkok Report) (Community screening)	Mahachai et al. (2018)
Screen and treat	Communities or individuals with a high risk of gastric cancer	<i>Strong</i> ^a : Europe (Maastricht V/Florence Consensus Report 20) Italy (II Working Group Consensus Report) ^b	Malfertheiner et al. (2017) Zagari et al. (2015)
		Moderate ^c : Taiwan (Convened by the Steering Committee)	Sheu et al. (2017)
		Need more research: Chile	Torres et al. (2016)
Screen and treat	Populations with low and/or intermediate gastric cancer risk	<i>Moderate</i> ^c : Taiwan (intermediate risk only) <i>Weak recommendation</i> : Europe	Sheu et al. (2017) Malfertheiner et al. (2017)
Screen and treat	Individuals with family history of gastric cancer (e.g., first-degree relatives of gastric cancer patients)	<i>Strong or recommended</i> : 10 ASEAN countries, Italy ^b , Brazil, China (Chinese Society of Gastroenterology), South Korea (Korean College of <i>Helicobacter</i> and Upper Gastrointestinal Research Guideline Steering Committee)	Coelho et al. (2013); Lee (2014a); Mahachai et al. (2018); Zagari et al. (2015)
		<i>Insufficient</i> : United States	Chey et al. (2017)
Screen and treat	Immigrants from high-risk regions	<i>Recommended</i> : Canada (Canadian <i>Helicobacter</i> Study Group and Canadian Cancer Society)	Taylor et al. (2014) [cites CCS (2014)]
Screen and treat	Patients with symptoms of gastric diseases	<i>Strong or recommended</i> : Italy, China, South Korea <i>Moderate</i> : Brazil <i>Insufficient</i> : United States	Lee (2014a); Zagari et al. (2015) Coelho et al. (2013) Chey et al. (2017)

Type of Recommendation	Population	Strength of the Association/Region	References
Screen and treat	Patients with precancerous gastric lesions	<i>Strong</i> : 10 ASEAN countries	Mahachai et al. (2018)
		<i>Moderate</i> : Brazil	Coelho et al. (2013)
		<i>“Favors”</i> : Chile	Torres et al. (2016)
		<i>Weak</i> : South Korea	Choi (2013)
Treatment of cancer	Patients with gastric MALT lymphoma	<i>Strong or recommended</i> : 10 ASEAN countries, Taiwan, China, South Korea, Japan, United States	Chey et al. (2017); Lee (2014a); Mahachai et al. (2018); Sheu et al. (2017)
Secondary prevention and/or treatment of cancer	Patients with gastric cancer	<i>Strong or recommended</i> : Italy, Chile, China, South Korea, Japan, United States	Chey et al. (2017); Lee (2014a); Torres et al. (2016); Zagari et al. (2015)

ASEAN = Association of Southeast Asian Nations. The 10 members are Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.

^aSome reports referred to this as Group A recommendation.

^bStatement was “that the recommendation should be considered.”

^cSome reports referred to this as Group B recommendation.

Overall, there was consensus across the working groups that *H. pylori* eradication could reduce but not completely eliminate *H. pylori*-induced cancer. Most, but not all, working groups recommended screening and treatment programs for individuals with a high risk of non-cardia gastric cancer (including those with a family history of non-cardia gastric cancer or immigrants from high-risk regions); however, working groups from some countries (such as the United States and Chile) thought more research was needed. Some working groups recommended that screening and treatment programs include patients without advanced gastric lesions, and other groups (e.g., South Korea) recommended treatment of patients with intestinal metaplasia. Most groups recommended that the cancer-treatment program treat *H. pylori* among patients with gastric MALT lymphoma as well as non-cardia gastric cancer. One working group has recommended against general screening and treatment in children and adolescents; but it recommended that those with gastric or duodenal ulcers should be treated with a regimen tailored to the child or adolescent (Jones et al. 2017). The groups also recommended that endoscopic or histological surveillance may be needed after treatment (Lee et al. 2007; Sheu et al. 2017).

3.2.2. Screening and Treatment Programs

Worldwide, only a few countries have instituted gastric cancer prevention programs, either regionally or nationwide, and only some of these include *H. pylori* screening and treatment. The majority of these programs are in Asia. In Japan, which has high rates of stomach cancer, but also one of the highest 5-year survival rates, at 90% (Asaka 2014), an early stomach-cancer detection screening program using indirect barium contrast imaging has been in place for many years, although participation rates have been low. In 2013, after a successful trial showed that eradicating *H. pylori* reduced the incidence of secondary non-cardia gastric cancer, Japan approved national health insurance coverage of *H. pylori* eradication therapy for all patients with gastric MALT lymphoma, early non-cardia gastric cancer, idiopathic thrombocytopenia purpura, gastric and duodenal ulcers, and chronic gastritis, who are diagnosed via endoscopic examination. In South Korea, a national program was begun in the early 2000s to provide

stomach-cancer screening every 2 years for all residents aged 40 and over. Participation rates have increased each year; in 2011, about half of those eligible were screened (Suh et al. 2013).

In 2006, Chile became the first Latin American country to institute a program that provides stomach-cancer screening to symptomatic people aged 40 and over. The program provides endoscopic examination for *H. pylori* detection, biopsy, and treatment (Ferrecchio 2014). This program has had limited success, as population coverage has been small (Torres et al. 2016). The program is currently under review, and other strategies are being considered, including general-population screening and eradication in high-risk populations, accompanied by more efficient early-detection methods.

While most current gastric cancer prevention programs are symptoms based and include endoscopy or imaging as the primary screening for gastric cancer, several smaller scale efforts in Taiwan have included a general-population stomach-cancer prevention program combining *H. pylori* screening and endoscopy to older populations considered to be at highest risk for gastric cancer. The first program was pilot-tested on Matsu Island, a high-risk population, with promising results (Lee et al. 2013; Lee and Lin 2017). Based on these results, two additional regions of Taiwan have implemented a similar program combining the urea breath test for *H. pylori* and endoscopic screening for stomach cancer among those aged 50 to 69 (Lee 2014b). Another region in Taiwan is conducting a large-scale randomized controlled trial that combines colon-cancer screening with *H. pylori* screening, with treatment for those who test positive (Lee and Lin 2017).

3.3. Summary of the Recommendations of International Expert Working Groups (Including the IARC Working Group)

Given the strong link between *H. pylori* and non-cardia gastric cancer, as well as the high global burden of disease, international expert working groups have recommended that countries worldwide should devote additional public health resources to this disease. This global burden and the feasibility of treating the main cause of disease make *H. pylori* a possible target for intervention. Recent randomized trials have provided support for *H. pylori* eradication in the prevention of stomach cancer, while economic analyses have shown it to be cost-effective in many populations, particularly high-risk populations. Several additional large, randomized trials currently under way may add to the evidence. As well as preventing non-cardia gastric cancer (and gastric MALT lymphoma), *H. pylori* eradication may also prevent diseases such as dyspepsia and peptic ulcers, increasing its cost-effectiveness.

Although evidence for the effectiveness of screening and treatment in reducing stomach-cancer incidence is increasing, caution should be exercised in any planned intervention program. Local antibiotic resistance patterns should be taken into account in the choice of treatment method, as well as in targeting of the appropriate populations for intervention. Other potential consequences of eradication therapy must also be considered in any program, including increases in antibiotic resistance, changes in the natural gastrointestinal flora, and increases in diseases on which *H. pylori* may have a beneficial effect, such as GERD and esophageal cancer. Before implementation, any planned programs should consider objective assessments of feasibility, effectiveness, program acceptance, cost-effectiveness, and adverse consequences relevant to the local area.

References

- AlMalki AS. 2008. *Helicobacter pylori* eradication in nonulcer dyspepsia: Does it really matter? Saudi J Gastroenterol. 14(2):93-95. <http://dx.doi.org/10.4103/1319-3767.39628>
- Anderson WF, Rabkin CS, Turner N, Fraumeni JF, Jr., Rosenberg PS, Camargo MC. 2018. The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. J Natl Cancer Inst. 110(6):1-8. <http://dx.doi.org/10.1093/jnci/djx262>
- Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M. 2013. Screening for gastric cancer and surveillance of premalignant lesions: A systematic review of cost-effectiveness studies. Helicobacter. 18(5):325-337. <http://dx.doi.org/10.1111/hel.12050>
- Asaka M. 2014. Chapter 1.2. Strategy to eliminate gastric cancer deaths in Japan. In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 21-27.
- Aziz RK, Khalifa MM, Sharaf RR. 2015. Contaminated water as a source of *Helicobacter pylori* infection: A review. J Adv Res. 6(4):539-547. <http://dx.doi.org/10.1016/j.jare.2013.07.007>
- Balakrishnan M, George R, Sharma A, Graham DY. 2017. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep. 19(8):36. <http://dx.doi.org/10.1007/s11894-017-0575-8>
- Biranjia-Hurdoyal SD, Seetulsingh-Goorah SP. 2016. Performances of four *Helicobacter pylori* serological detection kits using stool antigen test as gold standard. PLoS One. 11(10):e0163834. <http://dx.doi.org/10.1371/journal.pone.0163834>
- Bjorkman DJ. 2017. Racial and ethnic disparities in gastric cancer risk. NEJM Journal Watch. <https://production.jwatch.org/na43129/2017/01/17/racial-and-ethnic-disparities-gastric-cancer-risk>. [Accessed on March 14, 2018]
- Blase JL, Campbell PT, Gapstur SM, Pawlita M, Michel A, Waterboer T, Teras LR. 2016. Prediagnostic *Helicobacter pylori* antibodies and colorectal cancer risk in an elderly, Caucasian population. Helicobacter. 21(6):488-492. <http://dx.doi.org/10.1111/hel.12305>
- Bui D, Brown HE, Harris RB, Oren E. 2016. Serologic evidence for fecal-oral transmission of *Helicobacter pylori*. Am J Trop Med Hyg. 94(1):82-88. <http://dx.doi.org/10.4269/ajtmh.15-0297>
- Camargo MC, Yopez MC, Ceron C, Guerrero N, Bravo LE, Correa P, Fontham ET. 2004. Age at acquisition of *Helicobacter pylori* infection: Comparison of two areas with contrasting risk of gastric cancer. Helicobacter. 9(3):262-270. <http://dx.doi.org/10.1111/j.1083-4389.2004.00221.x>
- Canadian Cancer Society (CCS). 2014. *Helicobacter pylori* (H. pylori). Canadian Cancer Society. <https://www.cancer.ca/en/cancer-information>. [Retrieved on July 30, 2014]
- Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. 2011. *Helicobacter pylori* infection and gastric cardia cancer: Systematic review and meta-analysis. Cancer Causes Control. 22(3):375-387. <http://dx.doi.org/10.1007/s10552-010-9707-2>

Centers for Disease Control and Prevention (CDC). 2016. List of vaccines used in United States. Atlanta, GA: Centers for Disease Control and Prevention.

<https://www.cdc.gov/vaccines/vpd/vaccines-list.html>. [Last updated: November 22, 2016]

Chen XZ, Schöttker B, Castro FA, Chen H, Zhang Y, Holleczeck B, Brenner H. 2016. Association of *Helicobacter pylori* infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: A ten-year follow-up of the ESTHER cohort study. *Oncotarget*. 7(13):17182-17193. <http://dx.doi.org/10.18632/oncotarget.7946>

Cheng HC, Wang JD, Chen WY, Chen CW, Chang SC, Sheu BS. 2015. *Helicobacter pylori* test-and-treat program can be cost-effective to prevent gastric cancer in Taiwanese adults: Referred to the nationwide reimbursement database. *Helicobacter*. 20(2):114-124.

<http://dx.doi.org/10.1111/hel.12185>

Chey WD, Leontiadis GI, Howden CW, Moss SF. 2017. ACG Clinical Guideline: Treatment of *Helicobacter pylori* infection. *Am J Gastroenterol*. 112(2):212-239.

<http://dx.doi.org/10.1038/ajg.2016.563>

Choi IJ. 2013. Current evidence of effects of *Helicobacter pylori* eradication on prevention of gastric cancer. *Korean J Intern Med*. 28(5):525-537.

Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH. 2018. *Helicobacter pylori* therapy for the prevention of metachronous gastric cancer. *N Engl J Med*. 378(12):1085-1095. <http://dx.doi.org/10.1056/NEJMoa1708423>

Choi IJ, Park JY, Herrero R. 2014a. Chapter 4.3. Effect of *Helicobacter pylori* eradication on gastric cancer prevention in the Republic of Korea: A randomized controlled clinical trial. In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 154-160.

Choi J, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, Jung HC. 2014b. Eradication of *Helicobacter pylori* after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. *Clin Gastroenterol Hepatol*. 12(5):793-800.

<http://dx.doi.org/10.1016/j.cgh.2013.09.057>

Coelho LG, Maguinilk I, Zaterka S, Parente JM, Passos MCF, Moraes-Filho JPP. 2013. 3rd Brazilian consensus on *Helicobacter pylori*. *Arq Gastroenterol*. 50(2):1-17.

<http://dx.doi.org/10.1590/S0004-28032013005000001>

Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. 2015. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. *Gut*. 64(12):1881-1888.

<http://dx.doi.org/10.1136/gutjnl-2014-308915>

Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravalle G, Dammacco F. 2013. *H. pylori* infection and gastric cancer: State of the art (review). *Int J Oncol*. 42(1):5-18.

<http://dx.doi.org/10.3892/ijo.2012.1701>

Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD et al. 2000. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant

supplements and anti-*Helicobacter pylori* therapy. J Natl Cancer Inst. 92(23):1881-1888.

<http://dx.doi.org/10.1093/jnci/92.23.1881>

Cover TL. 2016. *Helicobacter pylori* diversity and gastric cancer risk. MBio. 7(1):e01869-01815.

<http://dx.doi.org/10.1128/mBio.01869-15>

de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. 2012. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 13(6):607-615. [http://dx.doi.org/10.1016/S1470-2045\(12\)70137-7](http://dx.doi.org/10.1016/S1470-2045(12)70137-7)

de Sanjose S, Dickie A, Alvaro T, Romagosa V, Garcia Villanueva M, Domingo-Domenech E, Fernandez de Sevilla A, El-Omar E. 2004. *Helicobacter pylori* and malignant lymphoma in Spain. Cancer Epidemiol Biomarkers Prev. 13(6):944-948.

Derakhshan MH, Arnold M, Brewster DH, Going JJ, Mitchell DR, Forman D, McColl KE. 2016. Worldwide inverse association between gastric cancer and esophageal adenocarcinoma suggesting a common environmental factor exerting opposing effects. Am J Gastroenterol. 111(2):228-239. <http://dx.doi.org/10.1038/ajg.2015.405>

Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbinteanu-Braticevici C. 2017. *Helicobacter pylori* infection: Old and new. J Med Life. 10(2):112-117.

Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. 2016. Eradication of *Helicobacter pylori* and gastric cancer: A systematic review and meta-analysis of cohort studies. J Natl Cancer Inst. 108(9). <http://dx.doi.org/10.1093/jnci/djw132>

Dore MP, Pes GM, Bassotti G, Usai-Satta P. 2016. Dyspepsia: When and how to test for *Helicobacter pylori* infection. Gastroenterol Res Pract. 2016:8463614.

<http://dx.doi.org/10.1155/2016/8463614>

Epplein M, Pawlita M, Michel A, Peek RM, Jr., Cai Q, Blot WJ. 2013. *Helicobacter pylori* protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 22(11):1964-1974. <http://dx.doi.org/10.1158/1055-9965.EPI-13-0702>

Epplein M, Signorello LB, Zheng W, Peek RM, Jr., Michel A, Williams SM, Pawlita M, Correa P, Cai Q, Blot WJ. 2011. Race, African ancestry, and *Helicobacter pylori* infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev. 20(5):826-834. <http://dx.doi.org/10.1158/1055-9965.EPI-10-1258>

Epplein M, Zheng W, Li H, Peek RM, Jr., Correa P, Gao J, Michel A, Pawlita M, Cai Q, Xiang YB et al. 2014. Diet, *Helicobacter pylori* strain-specific infection, and gastric cancer risk among Chinese men. Nutr Cancer. 66(4):550-557. <http://dx.doi.org/10.1080/01635581.2014.894096>

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2013. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer (IARC). <http://globocan.iarc.fr>.

Fernández de Larrea-Baz N, Michel A, Romero B, Pérez-Gómez B, Moreno V, Martín V, Dierssen-Sotos T, Jiménez-Moleón JJ, Castilla J, Tardón A et al. 2017. *Helicobacter pylori*

antibody reactivities and colorectal cancer risk in a case-control study in Spain. *Front Microbiol.* 8:888. <http://dx.doi.org/10.3389/fmicb.2017.00888>

Ferreccio C. 2014. Chapter 1.4 The regional status of current or planned gastric cancer prevention strategies in Latin America. In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 37-43.

Figura N, Marano L, Moretti E, Ponzetto A. 2016. *Helicobacter pylori* infection and gastric carcinoma: Not all the strains and patients are alike. *World J Gastrointest Oncol.* 8(1):40-54. <http://dx.doi.org/10.4251/wjgo.v8.i1.40>

Fischbach W. 2014. Gastric MALT lymphoma - update on diagnosis and treatment. *Best Pract Res Clin Gastroenterol.* 28(6):1069-1077. <http://dx.doi.org/10.1016/j.bpg.2014.09.006>

Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L et al. 2017. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study. *JAMA Oncol.* 3(4):524-548. <http://dx.doi.org/10.1001/jamaoncol.2016.5688>

Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. 2014. *Helicobacter pylori* eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials. *BMJ.* 348:g3174. <http://dx.doi.org/10.1136/bmj.g3174>

Forman D, Sierra M. 2014. Introduction. The current and projected global burden of gastric cancer. In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 5-15.

Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, Rogers AB, Neish AS, Collier-Hyams L, Perez-Perez GI, Hatakeyama M et al. 2005. Activation of beta-catenin by carcinogenic *Helicobacter pylori*. *Proc Natl Acad Sci U S A.* 102(30):10646-10651. <http://dx.doi.org/10.1073/pnas.0504927102>

Franco AT, Johnston E, Krishna U, Yamaoka Y, Israel DA, Nagy TA, Wroblewski LE, Piazzuelo MB, Correa P, Peek RM, Jr. 2008. Regulation of gastric carcinogenesis by *Helicobacter pylori* virulence factors. *Cancer Res.* 68(2):379-387. <http://dx.doi.org/10.1158/0008-5472.CAN-07-0824>

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M et al. 2008. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. *Lancet.* 372(9636):392-397. [http://dx.doi.org/10.1016/S0140-6736\(08\)61159-9](http://dx.doi.org/10.1016/S0140-6736(08)61159-9)

Fukui T, Okazaki K, Tamaki H, Kawasaki K, Matsuura M, Asada M, Nishi T, Uchida K, Iwano M, Ohana M et al. 2004. Immunogenetic analysis of gastric MALT lymphoma-like lesions induced by *Helicobacter pylori* infection in neonatally thymectomized mice. *Lab Invest.* 84(4):485-492. <http://dx.doi.org/10.1038/labinvest.3700056>

- Gawin A, Wex T, Lawniczak M, Malfertheiner P, Starzynska T. 2012. [Helicobacter pylori infection in pancreatic cancer]. Pol Merkuriusz Lekarski. 32(188):103-107.
- Gisbert JP, Greenberg ER. 2014. Chapter 3.2. Potential regimens for the mass eradication of Helicobacter pylori infection. In: Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 95-110.
- González CA, Megraud F, Buissonniere A, Lujan Barroso L, Agudo A, Duell EJ, Boutron-Ruault MC, Clavel-Chapelon F, Palli D, Krogh V et al. 2012. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: The Eurgast-EPIC project. Ann Oncol. 23(5):1320-1324.
<http://dx.doi.org/10.1093/annonc/mdr384>
- Graham DY. 2015. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 148(4):719-731. <http://dx.doi.org/10.1053/j.gastro.2015.01.040>
- Helicobacter Cancer Collaborative Group. 2001. Gastric cancer and Helicobacter pylori: A combined analysis of 12 case control studies nested within prospective cohorts. Gut. 49(3):347-353. <http://dx.doi.org/10.1136/gut.49.3.347>
- Hernández DBP, Sabogal IAR, Arenas JDT. 2014. Efficacy of eradicating Helicobacter pylori for prevention of gastric cancer: Systematic review and meta-analysis. Rev Colomb Gastroenterol. 29(3):262-269.
- Herrero R, Park JY, Forman D. 2014. The fight against gastric cancer - the IARC Working Group report. Best Pract Res Clin Gastroenterol. 28(6):1107-1114.
<http://dx.doi.org/10.1016/j.bpg.2014.10.003>
- Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY et al. 2017. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 153(2):420-429.
<http://dx.doi.org/10.1053/j.gastro.2017.04.022>
- Hsu WY, Lin CH, Lin CC, Sung FC, Hsu CP, Kao CH. 2014. The relationship between Helicobacter pylori and cancer risk. Eur J Intern Med. 25(3):235-240.
<http://dx.doi.org/10.1016/j.ejim.2014.01.009>
- Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. 2017. Systematic review with meta-analysis: The global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 46(9):773-779. <http://dx.doi.org/10.1111/apt.14319>
- Huang J, Zagai U, Hallmans G, Nyrén O, Engstrand L, Stolzenberg-Solomon R, Duell EJ, Overvad K, Katzke VA, Kaaks R et al. 2017. Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: A nested case-control study. Int J Cancer. 140(8):1727-1735. <http://dx.doi.org/10.1002/ijc.30590>
- Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. 2003. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 125(6):1636-1644.
<http://dx.doi.org/10.1053/j.gastro.2003.08.033>

International Agency for Research on Cancer (IARC). 2012. *Helicobacter pylori*. In: Biological Agents. Lyon, France: International Agency for Research on Cancer. p. 365-435.

International Agency for Research on Cancer (IARC). 2014. *Helicobacter pylori* eradication as a strategy for preventing gastric cancer. Lyon, France: International Agency for Research on Cancer. IARC Working Group, vol. 8.

Ishaq S, Nunn L. 2015. *Helicobacter pylori* and gastric cancer: A state of the art review. Gastroenterol Hepatol Bed Bench. 8(Suppl 1):S6-S14.

Jones NL, Koletzko S, Goodman K, Bontems P, Cadranet S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y et al. 2017. Joint ESPGHAN/NASPGHAN guidelines for the management of *Helicobacter pylori* in children and adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 64(6):991-1003. <http://dx.doi.org/10.1097/MPG.0000000000001594>

Kato S, Tachikawa T, Ozawa K, Konno M, Okuda M, Fujisawa T, Nakazato Y, Tajiri H, Inuma K. 2001. Urine-based enzyme-linked immunosorbent assay for the detection of *Helicobacter pylori* infection in children. Pediatrics. 107(6):E87. <http://dx.doi.org/10.1542/peds.107.6.e87>

Khalifa MM, Sharaf RR, Aziz RK. 2010. *Helicobacter pylori*: A poor man's gut pathogen? Gut Pathog. 2(1):2. <http://dx.doi.org/10.1186/1757-4749-2-2>

Krueger WS, Hilborn ED, Converse RR, Wade TJ. 2015. Environmental risk factors associated with *Helicobacter pylori* seroprevalence in the United States: A cross-sectional analysis of NHANES data. Epidemiol Infect. 143(12):2520-2531. <http://dx.doi.org/10.1017/S0950268814003938>

Lansdorp-Vogelaar I, Sharp L. 2013. Cost-effectiveness of screening and treating *Helicobacter pylori* for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 27(6):933-947. <http://dx.doi.org/10.1016/j.bpg.2013.09.005>

Lee CW, Rickman B, Rogers AB, Ge Z, Wang TC, Fox JG. 2008. *Helicobacter pylori* eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 68(9):3540-3548. <http://dx.doi.org/10.1158/0008-5472.CAN-07-6786>

Lee SY. 2014a. Current progress toward eradicating *Helicobacter pylori* in East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea. World J Gastroenterol. 20(6):1493-1502. <http://dx.doi.org/10.3748/wjg.v20.i6.1493>

Lee YC. 2014b. Chapter 1.3 The regional status of current or planned gastric cancer prevention strategies in Taiwan, China. In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 28-36.

Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT. 2013. The benefit of mass eradication of *Helicobacter pylori* infection: A community-based study of gastric cancer prevention. Gut. 62(5):676-682. <http://dx.doi.org/10.1136/gutjnl-2012-302240>

Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. 2016. Association between *Helicobacter pylori* eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology. 150(5):1113-1124. <http://dx.doi.org/10.1053/j.gastro.2016.01.028>

Lee YC, Lin JT. 2017. Screening and treating *Helicobacter pylori* infection for gastric cancer prevention on the population level. *J Gastroenterol Hepatol*. 32(6):1160-1169.

<http://dx.doi.org/10.1111/jgh.13726>

Lee YC, Lin JT, Wu HM, Liu TY, Yen MF, Chiu HM, Wang HP, Wu MS, Hsiu-Hsi Chen T. 2007. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. *Cancer Epidemiol Biomarkers Prev*. 16(5):875-885.

<http://dx.doi.org/10.1158/1055-9965.EPI-06-0758>

Leja M, Axon A, Brenner H. 2016. Epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 21 Suppl 1:3-7. <http://dx.doi.org/10.1111/hel.12332>

Leja M, Park JY, Murillo R, Liepniece-Karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I et al. 2017. Multicentric randomised study of *Helicobacter pylori* eradication and pepsinogen testing for prevention of gastric cancer mortality: The GISTAR study. *BMJ Open*. 7(8):e016999. <http://dx.doi.org/10.1136/bmjopen-2017-016999>

Leja M, Park YY, Plummer M, Herrero R. 2014. Chapter 4.2. Multicentre randomized study of *Helicobacter pylori* eradication and pepsinogen testing for prevention of gastric cancer mortality (gastric cancer prevention study by predicting atrophic gastritis; GISTAR). In: *Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer*. Lyon, France: International Agency for Research on Cancer. p. 147-153.

Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. 2004. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on *Helicobacter pylori* eradication. *Gut*. 53(9):1244-1249.

<http://dx.doi.org/10.1136/gut.2003.034629>

Li Q, Liu J, Gong Y, Yuan Y. 2017. Association of CagA EPIYA-D or EPIYA-C phosphorylation sites with peptic ulcer and gastric cancer risks: A meta-analysis. *Medicine (Baltimore)*. 96(17):e6620. <http://dx.doi.org/10.1097/MD.00000000000006620>

Li WQ, Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX et al. 2014. Effects of *Helicobacter pylori* treatment on gastric cancer incidence and mortality in subgroups. *J Natl Cancer Inst*. 106(7). <http://dx.doi.org/10.1093/jnci/dju116>

Limburg PJ, Stolzenberg-Solomon RZ, Colbert LH, Perez-Perez GI, Blaser MJ, Taylor PR, Virtamo J, Albanes D. 2002. *Helicobacter pylori* seropositivity and colorectal cancer risk: A prospective study of male smokers. *Cancer Epidemiol Biomarkers Prev*. 11(10 Pt 1):1095-1099.

Liu H, Merrell DS, Semino-Mora C, Goldman M, Rahman A, Mog S, Dubois A. 2009. Diet synergistically affects *Helicobacter pylori*-induced gastric carcinogenesis in nonhuman primates. *Gastroenterology*. 137(4):1367-1379.e1361-1366. <http://dx.doi.org/10.1053/j.gastro.2009.07.041>

Logan RP, Walker MM. 2001. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of *Helicobacter pylori* infection. *BMJ*. 323(7318):920-922.

<http://dx.doi.org/10.1136/bmj.323.7318.920>

Long Parma D, Muñoz E, Ogden SM, Westin GF, Leach RJ, Thompson IM, Ramirez AG. 2017. *Helicobacter pylori* infection in Texas Hispanic and non-Hispanic white men: Implications for

gastric cancer risk disparities. *Am J Mens Health*. 11(4):1039-1045.

<http://dx.doi.org/10.1177/1557988317702038>

Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S et al. 2012. Fifteen-year effects of *Helicobacter pylori*, garlic, and vitamin treatments on gastric cancer incidence and mortality. *J Natl Cancer Inst*. 104(6):488-492.

<http://dx.doi.org/10.1093/jnci/djs003>

Machida-Montani A, Sasazuki S, Inoue M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Hanaoka T, Tsugane S. 2007. Atrophic gastritis, *Helicobacter pylori*, and colorectal cancer risk: A case-control study. *Helicobacter*. 12(4):328-332. <http://dx.doi.org/10.1111/j.1523-5378.2007.00513.x>

Maeda M, Moro H, Ushijima T. 2017. Mechanisms for the induction of gastric cancer by *Helicobacter pylori* infection: Aberrant DNA methylation pathway. *Gastric Cancer*. 20(Suppl 1):8-15. <http://dx.doi.org/10.1007/s10120-016-0650-0>

Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P et al. 2018. *Helicobacter pylori* management in ASEAN: The Bangkok consensus report. *J Gastroenterol Hepatol*. 33(1):37-56. <http://dx.doi.org/10.1111/jgh.13911>

Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY et al. 2017. Management of *Helicobacter pylori* infection-the Maastricht V/Florence consensus report. *Gut*. 66(1):6-30. <http://dx.doi.org/10.1136/gutjnl-2016-312288>

Malnick SD, Melzer E, Attali M, Duek G, Yahav J. 2014. *Helicobacter pylori*: Friend or foe? *World J Gastroenterol*. 20(27):8979-8985.

Mateos-Muñoz B, Pérez-de-la-Serna J, Ruiz-de-León A, Serrano-Falcón B, Casabona-Francés S, Velasco-Cerrudo A, Rey-Díaz-Rubio E. 2013. Enterohepatic *Helicobacter* other than *Helicobacter pylori*. *Rev Esp Enferm Dig*. 105(8):477-484. <http://dx.doi.org/10.4321/S1130-01082013000800006>

Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuolo MB, Camargo MC, Correa P. 2005. Long term follow up of patients treated for *Helicobacter pylori* infection. *Gut*. 54(11):1536-1540. <http://dx.doi.org/10.1136/gut.2005.072009>

Mera RM, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, Yopez MC, Realpe JL, Schneider BG, Morgan DR et al. 2017. Dynamics of *Helicobacter pylori* infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. *Gut*. 67(7):1239-1246. <http://dx.doi.org/10.1136/gutjnl-2016-311685>

Mitchell H, English DR, Elliott F, Gengos M, Barrett JH, Giles GG, Forman D. 2008. Immunoblotting using multiple antigens is essential to demonstrate the true risk of *Helicobacter pylori* infection for gastric cancer. *Aliment Pharmacol Ther*. 28(7):903-910.

- Moayyedi P. 2014. Chapter 3.3. Feasibility and cost-effectiveness of population-based *Helicobacter pylori* eradication. In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 111-121.
- Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC et al. 2013. Risk of recurrent *Helicobacter pylori* infection 1 year after initial eradication therapy in 7 Latin American communities. *JAMA*. 309(6):578-586. <http://dx.doi.org/10.1001/jama.2013.311>
- National Toxicology Program (NTP). 2016. Draft report on carcinogens concept. *Helicobacter pylori*: Chronic infection. Research Triangle Park, NC: National Toxicology Program.
- Nobel Prize. 2005. Press release: Nobel Prize in Physiology or Medicine for 2005 awarded to Barry J. Marshall and J. Robin Warren. Nobel Media AB. https://www.nobelprize.org/nobel_prizes/medicine/laureates/2005/press.html. [Last updated: October 3, 2005]
- Nozaki K, Shimizu N, Inada K, Tsukamoto T, Inoue M, Kumagai T, Sugiyama A, Mizoshita T, Kaminishi M, Tatematsu M. 2002. Synergistic promoting effects of *Helicobacter pylori* infection and high-salt diet on gastric carcinogenesis in Mongolian gerbils. *Jpn J Cancer Res*. 93(10):1083-1089. <http://dx.doi.org/10.1111/j.1349-7006.2002.tb01209.x>
- Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H et al. 2004. Progression of chronic atrophic gastritis associated with *Helicobacter pylori* infection increases risk of gastric cancer. *Int J Cancer*. 109(1):138-143. <http://dx.doi.org/10.1002/ijc.11680>
- Pan KF, Zhang L, Gerhard M, Ma JL, Liu WD, Ulm K, Wang JX, Zhang L, Zhang Y, Bajbouj M et al. 2016. A large randomised controlled intervention trial to prevent gastric cancer by eradication of *Helicobacter pylori* in Linqu County, China: Baseline results and factors affecting the eradication. *Gut*. 65(1):9-18. <http://dx.doi.org/10.1136/gutjnl-2015-309197>
- Park JB, Koo JS. 2014. *Helicobacter pylori* infection in gastric mucosa-associated lymphoid tissue lymphoma. *World J Gastroenterol*. 20(11):2751-2759. <http://dx.doi.org/10.3748/wjg.v20.i11.2751>
- Park JY, Forman D, Greenberg ER, Herrero R. 2013. *Helicobacter pylori* eradication in the prevention of gastric cancer: Are more trials needed? *Curr Oncol Rep*. 15(6):517-525. <http://dx.doi.org/10.1007/s11912-013-0341-5>
- Park JY, Nam BH, Herrero R, Choi IJ. 2017. Effect of *Helicobacter pylori* eradication on gastric cancer prevention in Korea: A randomized controlled clinical trial. In: Matsui S, Crowley J, editors. *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*. Singapore: Springer. p. 315-330.
- Parsonnet J. 2014. Chapter 2.2. Are there benefits of *Helicobacter pylori* infection? In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 72-79.

- Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. 1994. *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med*. 330(18):1267-1271. <http://dx.doi.org/10.1056/NEJM199405053301803>
- Pereira MI, Medeiros JA. 2014. Role of *Helicobacter pylori* in gastric mucosa-associated lymphoid tissue lymphomas. *World J Gastroenterol*. 20(3):684-698. <http://dx.doi.org/10.3748/wjg.v20.i3.684>
- Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. 2015. Global burden of gastric cancer attributable to *Helicobacter pylori*. *Int J Cancer*. 136(2):487-490. <http://dx.doi.org/10.1002/ijc.28999>
- Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G, Hejna M, Scheithauer W. 1998. Association between *Helicobacter pylori* infection and pancreatic cancer. *Oncology*. 55(1):16-19. <http://dx.doi.org/10.1159/000011830>
- Reynders MB, Miendje Deyi VY, Dahma H, Scheper T, Hanke M, Decolvenaer M, Dediste A. 2012. Performance of individual *Helicobacter pylori* antigens in the immunoblot-based detection of *H. pylori* infection. *FEMS Immunol Med Microbiol*. 64(3):352-363. <http://dx.doi.org/10.1111/j.1574-695X.2011.00920.x>
- Risch HA, Lu L, Kidd MS, Wang J, Zhang W, Ni Q, Gao YT, Yu H. 2014. *Helicobacter pylori* seropositivities and risk of pancreatic carcinoma. *Cancer Epidemiol Biomarkers Prev*. 23(1):172-178. <http://dx.doi.org/10.1158/1055-9965.EPI-13-0447>
- Risch HA, Yu H, Lu L, Kidd MS. 2010. ABO blood group, *Helicobacter pylori* seropositivity, and risk of pancreatic cancer: A case-control study. *J Natl Cancer Inst*. 102(7):502-505. <http://dx.doi.org/10.1093/jnci/djq007>
- Rokkas T, Sechopoulos P, Pistiolas D, Kothonas F, Margantinis G, Koukoulis G. 2013. The relationship of *Helicobacter pylori* infection and colon neoplasia, on the basis of meta-analysis. *Eur J Gastroenterol Hepatol*. 25(11):1286-1294. <http://dx.doi.org/10.1097/MEG.0b013e328363d3cd>
- Romero-Gallo J, Harris EJ, Krishna U, Washington MK, Perez-Perez GI, Peek RM, Jr. 2008. Effect of *Helicobacter pylori* eradication on gastric carcinogenesis. *Lab Invest*. 88(3):328-336. <http://dx.doi.org/10.1038/labinvest.3700719>
- Sachs G, Scott DR, Wen Y. 2011. Gastric infection by *Helicobacter pylori*. *Curr Gastroenterol Rep*. 13(6):540-546. <http://dx.doi.org/10.1007/s11894-011-0226-4>
- Saito D, Boku N, Fujioka T, Fukuda Y, Matsushima Y, Sakaki N, Sato K, Sugiyama T, Takahashi S, Sato T et al. 2005. Impact of *H. pylori* eradication on gastric cancer prevention: Endoscopic results of the Japanese intervention trial (JITHP-Study): A randomized multi-center trial. *Gastroenterology*. 128(Suppl 2):A4.
- Schulte A, Pandeya N, Fawcett J, Fritschi L, Risch HA, Webb PM, Whiteman DC, Neale RE. 2015. Association between *Helicobacter pylori* and pancreatic cancer risk: A meta-analysis. *Cancer Causes Control*. 26(7):1027-1035. <http://dx.doi.org/10.1007/s10552-015-0595-3>

- Schulz TR, McBryde ES, Leder K, Biggs BA. 2014. Using stool antigen to screen for *Helicobacter pylori* in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One. 9(9):e108610. <http://dx.doi.org/10.1371/journal.pone.0108610>
- Servetas SL, Bridge DR, Merrell DS. 2016. Molecular mechanisms of gastric cancer initiation and progression by *Helicobacter pylori*. Curr Opin Infect Dis. 29(3):304-310. <http://dx.doi.org/10.1097/QCO.0000000000000248>
- Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI et al. 2017. Consensus on the clinical management, screening-to-treat, and surveillance of *Helicobacter pylori* infection to improve gastric cancer control on a nationwide scale. Helicobacter. 22(3). <http://dx.doi.org/10.1111/hel.12368>
- Shimoyama T, Takahashi R, Abe D, Mizuki I, Endo T, Fukuda S. 2010. Serological analysis of *Helicobacter hepaticus* infection in patients with biliary and pancreatic diseases. J Gastroenterol Hepatol. 25(Suppl 1):S86-89. <http://dx.doi.org/10.1111/j.1440-1746.2010.06224.x>
- Siao D, Somsouk M. 2014. *Helicobacter pylori*: Evidence-based review with a focus on immigrant populations. J Gen Intern Med. 29(3):520-528. <http://dx.doi.org/10.1007/s11606-013-2630-y>
- Simán JH, Engstrand L, Berglund G, Forsgren A, Florén CH. 2007. *Helicobacter pylori* and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol. 42(8):933-940. <http://dx.doi.org/10.1080/00365520601173863>
- Song ZQ, Zhou LY. 2015. *Helicobacter pylori* and gastric cancer: Clinical aspects. Chin Med J. 128(22):3101-3105. <http://dx.doi.org/10.4103/0366-6999.169107>
- Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, Albanes D. 2001. *Helicobacter pylori* seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst. 93(12):937-941. <http://dx.doi.org/10.1093/jnci/93.12.937>
- Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P et al. 2015. Kyoto global consensus report on *Helicobacter pylori* gastritis. Gut. 64(9):1353-1367. <http://dx.doi.org/10.1136/gutjnl-2015-309252>
- Suh M, Choi KS, Lee YY, Jun JK. 2013. Trends in cancer screening rates among Korean men and women: Results from the Korean National Cancer Screening Survey, 2004-2012. Cancer Res Treat. 45(2):86-94. <http://dx.doi.org/10.4143/crt.2013.45.2.86>
- Surveillance Epidemiology and End Results Program (SEER). 2018. Cancer stat facts: Stomach cancer. Washington, DC: National Cancer Institute. <https://seer.cancer.gov/statfacts/html/stomach.html>.
- Sutton P, Boag JM. 2018. Status of vaccine research and development for *Helicobacter pylori*. Vaccine. (ePub ahead of print).
- Taylor VM, Ko LK, Hwang JH, Sin MK, Inadomi JM. 2014. Gastric cancer in Asian American populations: A neglected health disparity. Asian Pac J Cancer Prev. 15(24):10565-10571. <http://dx.doi.org/10.7314/APJCP.2014.15.24.10565>

Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. 2017. A screening program to test and treat for *Helicobacter pylori* infection: Cost-utility analysis by age, sex and ethnicity. *BMC Infect Dis.* 17(1):156. <http://dx.doi.org/10.1186/s12879-017-2259-2>

Testerman TL, Morris J. 2014. Beyond the stomach: An updated view of *Helicobacter pylori* pathogenesis, diagnosis, and treatment. *World J Gastroenterol.* 20(36):12781-12808. <http://dx.doi.org/10.3748/wjg.v20.i36.12781>

Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. 2016. Review article: The global emergence of *Helicobacter pylori* antibiotic resistance. *Aliment Pharmacol Ther.* 43(4):514-533. <http://dx.doi.org/10.1111/apt.13497>

Torres J, Correa P, Herrero R, Piazzuelo MB, Ferreccio C. 2016. Population-based strategies for *Helicobacter pylori*-associated disease management: Latin American perspective. In: Backert S, Yamaoka Y, editors. *Helicobacter pylori* Research: From Bench to Bedside. Springer Japan. p. 503-518.

U.S. Environmental Protection Agency (USEPA). 2016. Contaminant Information Sheets (CISs) for the final fourth Contaminant Candidate List (CCL 4). Washington, DC: U.S. Environmental Protection Agency. EPA 815-R-16-003.

U.S. Food and Drug Administration (FDA). 2017. Vaccines licensed for use in the United States. U.S. Food and Drug Administration. <https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>. [Last accessed: December 7, 2017]

Wald NJ. 2014. Chapter 4.5. The treatment of *Helicobacter pylori* infection of the stomach in relation to the possible prevention of gastric cancer. In: *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer. p. 174-181.

Wang F, Sun MY, Shi SL, Lv ZS. 2014. *Helicobacter pylori* infection and normal colorectal mucosa-adenomatous polyp-adenocarcinoma sequence: A meta-analysis of 27 case-control studies. *Colorectal Dis.* 16(4):246-252. <http://dx.doi.org/10.1111/codi.12290>

Wang MY, Liu XF, Gao XZ. 2015. *Helicobacter pylori* virulence factors in development of gastric carcinoma. *Future Microbiol.* 10(9):1505-1516. <http://dx.doi.org/10.2217/fmb.15.72>

Wang X, Willén R, Svensson M, Ljungh A, Wadström T. 2003. Two-year follow-up of *Helicobacter pylori* infection in C57BL/6 and Balb/cA mice. *APMIS.* 111(4):514-522. <http://dx.doi.org/10.1034/j.1600-0463.2003.1110410.x>

Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY et al. 2004. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. *JAMA.* 291(2):187-194. <http://dx.doi.org/10.1001/jama.291.2.187>

Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, Liu WD, Feng GS, Zhang XD, Li J et al. 2012. Effects of selective COX-2 inhibitor and *Helicobacter pylori* eradication on precancerous gastric lesions. *Gut.* 61(6):812-818. <http://dx.doi.org/10.1136/gutjnl-2011-300154>

Wong IO, Schooling CM, Cowling BJ. 2014. Cost-effectiveness of *Helicobacter pylori* screening and treatment for gastric cancer in Hong Kong: A decision analytic approach. *Hong Kong Med J*. 20(Suppl 7):13-15.

Wu Q, Yang ZP, Xu P, Gao LC, Fan DM. 2013. Association between *Helicobacter pylori* infection and the risk of colorectal neoplasia: A systematic review and meta-analysis. *Colorectal Dis*. 15(7):e352-e364. <http://dx.doi.org/10.1111/codi.12284>

Wündisch T, Dieckhoff P, Greene B, Thiede C, Wilhelm C, Stolte M, Neubauer A. 2012. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by *Helicobacter pylori* eradication and followed for 10 years. *Gastroenterology*. 143(4):936-942; quiz e913-e914. <http://dx.doi.org/10.1053/j.gastro.2012.06.035>

Xie F, O'Reilly D, Ferrusi IL, Blackhouse G, Bowen JM, Tarride JE, Goeree R. 2009. Illustrating economic evaluation of diagnostic technologies: Comparing *Helicobacter pylori* screening strategies in prevention of gastric cancer in Canada. *J Am Coll Radiol*. 6(5):317-323. <http://dx.doi.org/10.1016/j.jacr.2009.01.022>

Yamaoka Y, Graham DY. 2014. *Helicobacter pylori* virulence and cancer pathogenesis. *Future Oncol*. 10(8):1487-1500. <http://dx.doi.org/10.2217/fon.14.29>

Yeh JM, Hur C, Ward Z, Schrag D, Goldie SJ. 2016. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: A cost-effectiveness analysis. *Gut*. 65(4):563-574. <http://dx.doi.org/10.1136/gutjnl-2014-308588>

Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. 2009. Exploring the cost-effectiveness of *Helicobacter pylori* screening to prevent gastric cancer in China in anticipation of clinical trial results. *Int J Cancer*. 124(1):157-166. <http://dx.doi.org/10.1002/ijc.23864>

Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. 2014. Effect of *Helicobacter pylori* eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: A meta-analysis. *Helicobacter*. 19(4):243-248. <http://dx.doi.org/10.1111/hel.12146>

Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, Oka M, Watanabe M, Enomoto S, Niwa T et al. 2014. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and *Helicobacter pylori* antibody titer. *Int J Cancer*. 134(6):1445-1457. <http://dx.doi.org/10.1002/ijc.28470>

You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y et al. 2006. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. *J Natl Cancer Inst*. 98(14):974-983. <http://dx.doi.org/10.1093/jnci/djj264>

Yu G, Murphy G, Michel A, Weinstein SJ, Männistö S, Albanes D, Pawlita M, Stolzenberg-Solomon RZ. 2013. Seropositivity to *Helicobacter pylori* and risk of pancreatic cancer. *Cancer Epidemiol Biomarkers Prev*. 22(12):2416-2419. <http://dx.doi.org/10.1158/1055-9965.EPI-13-0680>

Zagari RM, Romano M, Ojetti V, Stockbrugger R, Gullini S, Annibale B, Farinati F, Ierardi E, Maconi G, Rugge M et al. 2015. Guidelines for the management of *Helicobacter pylori* infection

in Italy: The III working group consensus report 2015. Dig Liver Dis. 47(11):903-912.

<http://dx.doi.org/10.1016/j.dld.2015.06.010>

Zeng M, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ, Guo G, Zhao ZJ, Li L, Wu DL et al. 2015. Efficacy, safety, and immunogenicity of an oral recombinant *Helicobacter pylori* vaccine in children in China: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 386(10002):1457-1464. [http://dx.doi.org/10.1016/S0140-6736\(15\)60310-5](http://dx.doi.org/10.1016/S0140-6736(15)60310-5)

Zhang Y, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H. 2012. *Helicobacter pylori* infection and colorectal cancer risk: Evidence from a large population-based case-control study in Germany. Am J Epidemiol. 175(5):441-450. <http://dx.doi.org/10.1093/aje/kwr331>

Zhou L, Lin S, Ding S, Huang X, Jin Z, Cui R, Meng L, Li Y, Zhang L, Guo C et al. 2014. Relationship of *Helicobacter pylori* eradication with gastric cancer and gastric mucosal histological changes: A 10-year follow-up study. Chin Med J (Engl). 127(8):1454-1458.

Zou QH, Li RQ. 2011. *Helicobacter pylori* in the oral cavity and gastric mucosa: A meta-analysis. J Oral Pathol Med. 40(4):317-324. <http://dx.doi.org/10.1111/j.1600-0714.2011.01006.x>

Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira D. 2009. Eradication therapy for *Helicobacter pylori* in patients with gastric MALT lymphoma: A pooled data analysis. Am J Gastroenterol. 104(8):1932-1937; quiz 1938. <http://dx.doi.org/10.1038/ajg.2009.314>

Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D. 2010a. Effects of *Helicobacter pylori* eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 8(2):105-110. <http://dx.doi.org/10.1016/j.cgh.2009.07.017>

Zullo A, Hassan C, Cristofari F, Perri F, Morini S. 2010b. Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: *Helicobacter pylori* and beyond. World J Gastrointest Oncol. 2(4):181-186. <http://dx.doi.org/10.4251/wjgo.v2.i4.181>

Zumkeller N, Brenner H, Chang-Claude J, Hoffmeister M, Nieters A, Rothenbacher D. 2007. *Helicobacter pylori* infection, interleukin-1 gene polymorphisms and the risk of colorectal cancer: Evidence from a case-control study in Germany. Eur J Cancer. 43(8):1283-1289. <http://dx.doi.org/10.1016/j.ejca.2007.03.005>

Abbreviations

ASEAN	Association of Southeast Asian Nations
BabA	blood group antigen binding adhesin A
CAG	chronic atrophic gastritis
CagA	cytotoxin-associated gene A
CI	confidence interval
COX 2	cyclooxygenase 2
CPS II	Cancer Prevention Study II
DNA	deoxyribonucleic acid
DYS	dysplasia
ELISA	enzyme-linked immunosorbent assay
FDA	U.S. Food and Drug Administration
FDASIA	Food and Drug Administration Safety and Innovation Act
GAIN	Generating Antibiotic Incentives Now
GERD	gastro-esophageal reflux disease
HAWC	Health Assessment Workspace Collaborative
HDI	human development index
HR	hazard ratio
IgA	immunoglobulin A
IgG	immunoglobulin G
IM	intestinal metaplasia
IQR	interquartile range
MALT	mucosa-associated lymphoid tissue
MNU	<i>N</i> -methyl- <i>N</i> -nitrosourea
NHANES	National Health and Nutrition Examination Survey (United States)
OR	odds ratio
ORoC	Office of the Report on Carcinogens
PPI	proton pump inhibitor
RoC	Report on Carcinogens
RR	relative risk
TGF- β	transforming growth factor beta
VacA	vacuolating cytotoxin A

Glossary

Animal reservoir: An animal in which an infectious agent (e.g., *H. pylori*) lives and multiplies in such a manner that it can be transmitted to a susceptible host.

Antrum: The lower part of the stomach, sometimes called the pyloric antrum.

ASEAN countries: Association of Southeast Asian Nations. The 10 members are Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.

Atrophic gastritis: The end stage of chronic gastritis, in which gastric glandular cells are lost and replaced by intestinal and fibrous tissues.

Barrett's esophagus: A complication of gastroesophageal reflux disease (GERD) in which the normal tissue lining the esophagus is altered to resemble the tissue that lines the intestine.

Birth cohort effect: Variations in a characteristic, such as *H. pylori* infection, among individuals that share a common year or range of years of birth.

Bismuth quadruple therapy: A combination of a bismuth salt, a proton pump inhibitor (PPI), and two antibiotics used to treat *H. pylori* infections.

Cardia: The opening that connects the esophagus and the upper part of the stomach or that part of the stomach connected to the esophagus.

Cardia gastric cancer: Cancer of the lining of the stomach found in the top part of the organ (i.e., the cardia).

Chemotaxis: Movement of an organism, for example an *H. pylori* bacterium, in response to a chemical stimulus, including acidity.

Clarithromycin triple therapy: A combination of clarithromycin (an antibiotic), amoxicillin (an antibiotic), and omeprazole (a proton pump inhibitor) used to treat *H. pylori* infections.

Corpus: The body of the stomach, which is the largest of the four parts that make up the stomach.

COX-2 inhibitor: A nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2 (COX-2) enzyme.

Enzyme-linked immunosorbent assay (ELISA): An immunological assay commonly used to measure antibodies in biological samples.

Enterohepatic tissues: The intestinal tract, biliary tree, and liver.

EPIYA motif: A polymorphic pattern of Glu-Pro-Ile-Tyr-Ala amino acid repeats that contains the main sites for phosphorylation of CagA.

Flagella (singular flagellum): A whip-like structure that allows a cell to move.

Gastritis: Inflammation, irritation, or erosion of the lining of the stomach.

Gram-negative bacteria: Bacteria that are not stained by the crystal violet dye used in the Gram stain protocol and thus appear red or pink due to the counterstain (usually safranin).

Helical: A geometric shape that curves continuously around a center point; for example, a line wrapped around a cylinder or a cone.

Immunoblot: A laboratory test that looks for antibodies the body makes against different molecules, or “antigens,” that are part of a bacteria, e.g., *H. pylori*.

INS-GAS transgenic mice: Mice that have been genetically modified to produce more gastrin (a peptide that increases the secretion of gastric acid).

Intervention studies: A test of preventive or therapeutic measure(s) in which study subjects are followed prospectively with one group of subjects receiving the treatment and the other serving as the control; the control group can receive no treatment, a placebo, or a standard treatment for comparison.

Life-years saved: A measure of the additional number of years that a person lives as a result of receiving a treatment.

Mucosal: Related to the mucosa, which is the thin skin that covers the inside surface of body parts such as the nose and mouth and produces mucus to protect them.

Non-cardia gastric cancer: Cancer of the lining of the stomach found in any part of the organ other than the top part (i.e., the cardia).

Peptic ulcers: Open sores that develop on the inside lining of the stomach and the upper portion of the small intestine.

Prevalence: The number of cases of a disease that are present in a particular population at a given time.

Sensitivity: The ability of a clinical test to correctly identify those patients with the disease.

Serology tests: Blood tests that look for antibodies, e.g., to *H. pylori*.

Specificity: The ability of a clinical test to correctly identify those patients without the disease.

Spiral: A shape consisting of curves, with each one above or wider than the one before.

Tissue biopsy: A sample of tissue removed from the body for closer examination, usually for diagnostic purposes.

Urease: An enzyme that converts urea to ammonia and carbon dioxide.

Appendix A. Literature Search Strategy

Table of Contents

A.1. Identification of Intervention Studies A-2

A.2. Identification of Cancer and Exposure Studies, Reviews, and Meta-analyses A-3

A.3. Updating the Literature Search A-4

Tables

Table A-1. Major Topics Searched..... A-2

Table A-2. The Full Search Strings for *H. pylori* Searches A-3

The objective of the literature-search approach was to identify published literature relevant for evaluating the potential carcinogenicity of the *Helicobacter pylori* (*H. pylori*) bacterium. As discussed in the *Helicobacter pylori* Concept Document (NTP 2016), this monograph relies on the IARC (2012) monograph and key studies published since the monograph. Two literature searches were conducted: (1) to identify key reviews or meta-analyses for updating exposure and mechanistic data and for determining whether a formal review of other cancer sites was merited and (2) to identify intervention and prevention studies published since the 2014 publication of the IARC working group report on *H. pylori* eradication.

A.1. Identification of Intervention Studies

A.1.1. General Approach

Database searching encompasses selecting databases and search terms, as well as conducting the searches. Searches of several citation databases generally use search terms for the individual topic of interest, along with search terms for cancer and/or specific topics, including epidemiological and mechanistic studies. A critical step in the process involves consultation with an information specialist to develop relevant search terms, which are used to search bibliographic databases. The IARC working group report on *H. pylori* eradication was published in 2014, so PubMed, Web of Science, and Scopus were searched for new information about *H. pylori* from 2013 through 2017. Table A-1 highlights the general concepts searched, with selected example terms.

Table A-1. Major Topics Searched

Topics	Example Terms
H. pylori	H-pylori, Helicobacter pylori, Helicobacter-pylori
Intervention/prevention	Controlled before-after studies, Interrupted time series analysis, Early medical intervention, Treatment, Intervention, Therapy, Prevention
Study type and topics	Meta-analysis, Clinical trial, Public health surveillance, Medical economics, Markov chains, Statistical models, Health care costs, Cost-benefit analysis, Review, Treatment outcome
Cancer	Neoplasms, Carcinogenicity tests, Carcinogens

The large and complex body of literature for *H. pylori* was searched through the use of narrowing terms for the relevant major topics within the bibliographic databases. The results were then processed in EndNote to remove duplicates, before being transferred to Health Assessment Workspace Collaborative (HAWC), a computational content management system, for screening.

The bibliographic database search results (1,198 references) were processed in EndNote and then imported into HAWC for first- and second-tier screening. Relevant studies found through the citations in review articles and other secondary searches were also included. Tagging in HAWC categorized the useful articles into categories such as Health Assessment (66 references), Antibiotic intervention (31 references), Other Intervention (19 references), and so on.

A.1.2. Search Strings for *H. pylori* Searches

Each search detailed below was limited to publication years from 2013 to 2017 and were combined with the [RoC Cancer Filter](#).

Table A-2. The Full Search Strings for *H. pylori* Searches

Database	Search Terms
PubMed	((("Meta-Analysis"[pt] OR meta-analysis[tiab] OR Meta-Analyses[tiab] OR MetaAnalysis[tiab] OR metaanalyses[tiab]) OR ("Clinical Trial"[pt] OR Clinical-Trial*[tiab]) OR ("Public Health Surveillance"[mh] OR "Economics, Medical"[mh]) OR ("Markov Chains"[Mh] AND "Models, Statistical"[Mh] OR Markov-chain*[tiab]) OR ("Health Care Costs"[mh] OR "Cost-Benefit Analysis"[mh] OR cost-benefit[tiab]) OR "Review"[pt] OR "Treatment Outcome"[mh])) AND ((("Controlled Before-After Studies"[Mh] OR "Interrupted Time Series Analysis"[Mh] OR "Early Medical Intervention"[Mh] OR Treatment*[tiab] OR intervention*[tiab] OR therapies[tiab] OR Therapy[tiab] OR prevent*[tiab])) AND (H-pylori[tiab] OR " <i>Helicobacter pylori</i> "[mh] OR Helicobacter-pylori[tiab]))
Web of Science	(TS=("Meta-Analysis" OR "Meta-Analyses" OR "Metaanalysis" OR "metaanalyses" OR "Review" OR "Clinical Trial*" OR "Public Health Surveillance" OR "Medical Economics" OR "Markov Chain*" OR "Health Care Costs" OR "Cost-Benefit Analysis" OR cost-benefit OR "Review" OR "Treatment Outcome")) AND (TS=("Controlled Before-After Studies" OR "Interrupted Time Series Analysis" OR "Early Medical Intervention" OR Treatment* OR intervention* OR therapies OR Therapy OR prevent*)) AND (TS=(H-pylori OR " <i>Helicobacter pylori</i> "))
Scopus	(TITLE-ABS-KEY ("Meta-Analysis" OR "Meta-Analyses" OR "Metaanalysis" OR "metaanalyses" OR "Review" OR "Clinical Trial*" OR "Public Health Surveillance" OR "Medical Economics" OR "Markov Chain*" OR "Health Care Costs" OR "Cost-Benefit Analysis" OR cost-benefit OR "Review" OR "Treatment Outcome")) AND (TITLE-ABS-KEY ("Controlled Before-After Studies" OR "Interrupted Time Series Analysis" OR "Early Medical Intervention" OR Treatment* OR intervention* OR therapies OR Therapy OR prevent*)) AND (TITLE-ABS-KEY (H-pylori OR " <i>Helicobacter pylori</i> "))

A.2. Identification of Cancer and Exposure Studies, Reviews, and Meta-analyses

Literature on cancer and exposure studies, reviews, and meta-analyses related to *H. pylori* infection were identified through the use of narrowing terms for the relevant major topics within PubMed, and the resulting citations were saved directly into HAWC. HAWC was used to screen results and eliminate out-of-scope or duplicate references.

1. *Prevalence* searches in PubMed combined the MeSH term for *H. pylori* with the MeSH term for prevalence, limited to reviews published in the past 5 years, and 69 references were added to HAWC for evaluation.
2. *Diagnosis* searches used the *H. pylori* MeSH term and the diagnosis MeSH term, limited to review articles published since 01/01/2017, and 19 references were added to HAWC.
3. Finally, 368 recent reviews and meta-analyses for *H. pylori* were identified and added to HAWC for evaluation.

A.3. Updating the Literature Search

The literature searches were last updated in PubMed, Scopus, and Web of Science on January 5, 2018. No additional publications were recommended by the peer reviewers.

Appendix B. Summary of Human Studies of Pancreatic and Colorectal Cancer

Table of Contents

B.1. Pancreatic Cancer.....B-2

B.2. Colorectal Cancer.....B-2

As mentioned in the Objective and Methods, NTP also reviewed recent meta-analyses, systematic reviews, and other reviews evaluating the association of *H. pylori* infection and other types of cancer, primarily pancreatic and colorectal cancer. A short summary of the updated findings on pancreatic and colorectal cancer is provided below.

B.1. Pancreatic Cancer

The 2009 IARC evaluation of *H. pylori* included four nested case-control studies (see IARC (2012), [Table 2.21](#)) and one case-control study of pancreatic cancer (Raderer et al. 1998). Since that time, five case-control studies (Gawin et al. 2012; Risch et al. 2014; Risch et al. 2010; Schulte et al. 2015; Shimoyama et al. 2010), one nested case-control study (Huang et al. 2017), two cohort studies (Chen et al. 2016; Hsu et al. 2014), and an update of a nested case-control study [Yu et al. (2013), which updated Stolzenberg-Solomon et al. (2001)] were identified. In addition, several recent meta-analyses were identified, of which the analysis by Schulte et al. (2015), which included 11 studies, was considered to be the most informative. This analysis reported meta ORs of 1.13 (95% CI = 0.86 to 1.50; 11 studies) for *H. pylori* infection and pancreatic cancer, 0.78 (95% CI = 0.67 to 0.91; 6 studies) for cytotoxin-associated gene A- (CagA-) positive strains, and 1.30 (95% CI = 1.02 to 1.65; 4 studies) for CagA-negative strains. The meta-analysis did not include the recent large nested case-control study by Huang et al. (2017), which did not find an association with *H. pylori* infection, or sub-analyses for Cag-negative or -positive strains, nor the ESTHER cohort study, which found non-significant elevated risks for *H. pylori* infection with CagA-negative strains (Chen et al. 2016). NTP considered the database of studies inadequate to evaluate the association between *H. pylori* infection and pancreatic cancer and did not conduct a formal evaluation.

B.2. Colorectal Cancer

The 2009 IARC working group evaluation of *H. pylori* included 12 case-control studies (IARC (2012), [Table 2.19](#)) and two nested case-control studies of colorectal cancer (IARC (2012), [Table 2.18](#)). Since that time, several meta-analyses and at least ten studies on colorectal cancer have been published. Recent meta-analyses that were specific for colorectal cancer (i.e., did not include colon adenoma) reported modestly increased colorectal cancer risks (~20% to 40%) with *H. pylori* infection [e.g., Rokkas et al. (2013); Wang et al. (2014); Wu et al. (2013)]; however, heterogeneity was observed, and many studies included in the analyses were small, cross-sectional, hospital-based case-control studies, or did not adjust for potential confounding factors. The most informative studies were four large population-based case-control studies (Fernández de Larrea-Baz et al. 2017; Machida-Montani et al. 2007; Zhang et al. 2012; Zumkeller et al. 2007), three nested case-control studies (Blase et al. 2016; Epplein et al. 2013; Limburg et al. 2002), and a cohort study (Chen et al. 2016) that reported adjusted risk estimates. Findings among these studies were inconsistent. Two population-based case-control studies in Germany (Zhang et al. 2012; Zumkeller et al. 2007) found positive associations with *H. pylori* infection. In addition, two nested case-control studies, an analysis within the U.S. Southern Community Cohort Study (Epplein et al. 2013), and an analysis of elderly Caucasians in the CPS-II Nutrition Cohort (Blase et al. 2016) reported positive associations with some specific *H. pylori* antigens but not *H. pylori* infection in general. Few studies have looked at specific antigens, and the results were inconsistent across studies. The other informative studies did not find an association

with *H. pylori* infection or specific antigens (Chen et al. 2016; Fernández de Larrea-Baz et al. 2017; Limburg et al. 2002; Machida-Montani et al. 2007). The evidence for an association between *H. pylori* infection and colon adenoma or polyps may be stronger, but adenoma is outside the scope of a cancer hazard evaluation. Based on this initial review, NTP did not conduct a formal evaluation of colorectal cancer.



National Toxicology Program

National Institute of Environmental Health Sciences

National Institutes of Health

P.O. Box 12233, MD K2-05

Durham, NC 27709

Tel: 984-287-3211

ntpwebrequest@niehs.nih.gov

<https://ntp.niehs.nih.gov>

ISSN 2331-267X